[{"disease": "NSCLC", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotoxic chemotherapy (carboplatin and paclitaxel) and gefitinib administration has not been determined. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "drug": "carboplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to systematically evaluate the efficacy and safety of gefitinib and cetuximab-based therapies in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The studies to be used for the comparisons were selected from the available literature on gefitinib and cetuximab-based therapies compared to conventional chemotherapy in patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "As regards efficacy, the risk ratio (RR) of objective response rate and 1-year survival rate between gefitinib and cetuximab-based therapies in patients with advanced NSCLC were 0.99 [95% confidence interval (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, and the mean difference of progression-free survival and overall survival (OS) were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; P=0.0331), respectively. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results demonstrated that cetuximab-based therapy was superior to gefitinib therapy in terms of OS and inferior to gefitinib therapy in terms of AEs, whereas there were no significant differences in terms of efficacy and safety between the two therapies on other endpoints adopted for advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients' prognosis and quality of life (QoL). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The medical charts of 138 consecutive patients with advanced NSCLC harboring sensitive EGFR mutations, who underwent gefitinib treatment, were reviewed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for NSCLC patients with EGFR activating mutation as first-line therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "ET-1 increased NSCLC clonal growth, whereas BQ123, ZD4054, lapatinib or gefitinib inhibited proliferation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Targeted therapies directed against epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and afatinib, achieved important improvements in EGFR mutated NSCLC with favorable toxicity profile. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotoxic chemotherapy (carboplatin and paclitaxel) and gefitinib administration has not been determined. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Three EGFR-TKIs, namely afatinib, erlotinib and gefitinib, are currently available for the treatment of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Another trial is now investigating the bene\ufb01cial effects of curcumin plus gefitinib or erlotinib for EGFR-mutant NSCLC, although this trial is ongoing. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The subjects studied were 74 NSCLC patients with common EGFR mutations treated with gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR-7 in patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients with stage I-II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III-IV disease. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our findings suggest that serum and expression levels of miR-7 in the tissue were closely associated with tumor staging and the therapeutic effects of gefitinib in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, detection of microRNA-200b may predict the inhibitory effect of gefitinib on NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NRP2b knockdown attenuated the acquisition of resistance to the EGFR inhibitor gefitinib in cultured NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Polyphyllin II(PP II) is the main steroidal saponin constituent which derives from the root of Paris polychylia.OBJECTIVE: We examined the sensitizing effect of PP II to gefitinib on proliferation, apoptosis, PI3K/Akt/mTOR signaling pathway and tumor growth on gefitinib-resistant NSCLC in vitro and in vivo. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "It provides a potential new strategy to overcome gefitinib resistance for EGFR-TKI resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The non-small cell lung cancer (NSCLC) patients harbor mutations in the epidermal growth factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib, and show improved progression-free survival. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant non-small cell lung cancer (NSCLC) patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We explored the role of miR-200c in modulating the sensitivity of gefitinib-resistant NSCLC cells and examined the underlying mechanism. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results provided insights into the functions of miR-200c and offered an alternate approach in treating gefitinib-resistance NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Unfortunately, most NSCLC patients inevitably develop gefitinib resistance during treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we showed that miR-124, a tumor suppressor, was significantly down-regulated in gefitinib-resistant NSCLC patients and cell lines compared with gefitinib-sensitive patients and cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of the study was to examine the drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In total, 156 NSCLC patients without surgical treatment were selected, including 117 cases of adenocarcinoma (75%), to receive single gefitinib 0.25 g/day or combined with platinum chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, gefitinib-targeted therapy in NSCLC showed certain drug resistance, which may not be related to the response. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The enhancement of ROS generation in H1650 and H1975 gefitinib-resistant NSCLC cells leads to impairment of growth and induction of apoptosis, whereas modulation of EGFR degradation and its downstream signalling pathways by Shikonin contributes to its anti-tumour properties in H1975 gefitinib-resistant NSCLC cells (with T790M and L858R activating mutations). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings indicate that Shikonin can be an effective small molecule treating gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Most gefitinib-treated patients with non-small cell lung cancer (NSCLC) would eventually develop resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study we investigated whether LC capilliposide in combination with gefitinib could overcome the resistance of NSCLC cells to gefitinib and identified the signaling pathways involved. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Treatment with LC capilliposide alone inhibited the growth of a panel of NSCLC cell lines (PC-9, H460, H1975, H1299 and PC-9-GR) sensitive or resistant to gefitinib with IC50 values in the range of \u03bcg/mL. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "LC capilliposide can restore the cells' sensitivity to gefitinib through modulation of pAKT levels, suggesting that a combination of LC capilliposide and gefitinib may be a promising therapeutic strategy to overcome gefitinib resistance in NSCLCs with a T790M mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by gefitinib, suggesting OCT4 may contribute to gefitinib resistance in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The study included 33 patients with EGFR-positive NSCLC treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we identified that miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer (NSCLC) patients comparing gefitinib-sensitive ones. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The miR-543 may represent a potential therapeutic target for gefitinib-resistant NSCLC intervention. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We retrospectively reviewed 183 Japanese patients with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor-na\u00efve non-small cell lung cancer (NSCLC) harboring EGFR mutations, who received gefitinib monotherapy between July 2007 and February 2014. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: These results suggest that being overweight may induce hepatic dysfunction during gefitinib monotherapy in Japanese patients with EGFR-mutated NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus, we concluded that microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in NSCLC cells and restoration of microRNA-520a-3p might be a therapeutic strategy to reverse gefitinib resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: We observed 70 patients with EGFR-mutated (EGFR-M+) non-small cell lung cancer (NSCLC) receiving single-agent gefitinib in a routine clinical setting; 56 patients were experiencing RECIST progression at the time of the analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: This study confirms that continued administration of gefitinib beyond progression is a viable treatment option for some patients with EGFR-M+ NSCLC, in particular those who cannot be rescued by novel EGFR mutation-specific inhibitors such as osimertinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This case report describes the effects of a Korean herbal medicine regimen combined with gefitinib in a patient with NSCLC and bone metastasis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that a combination of Korean herbal medicines and gefitinib may be an effective therapeutic option for patients with advanced NSCLC and bone metastasis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This case report describes the effects of a Korean herbal medicine regimen combined with gefitinib in a patient with NSCLC and bone metastasis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that a combination of Korean herbal medicines and gefitinib may be an effective therapeutic option for patients with advanced NSCLC and bone metastasis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We aimed to determine the effect of combining IFN-\u03b1 with gefitinib in human non-small cell lung cancer (NSCLC) cell lines (A549, H1299, HCC827) with different EGFR and K-Ras gene statuses. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The results might confirm the hypothesis that IFN-\u03b1 induces gefitinib sensitivity of NSCLC, and IFN-\u03b1 inhibits phosphorylation of STAT3, which may be dependent on EGFR signal activation playing a role in the reduction of gefitinib sensitivity after IFN-\u03b1 treatment in NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/non-small cell lung cancer/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A phase II trial was conducted in patients with stage III/IV NSCLC, to assess the efficacy, safety and impact on quality of life (QoL) and disease-related symptoms of gefitinib rechallenge. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The failure of targeted therapy due to the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is considered a major problem in the treatment of non-small cell lung cancer (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Collectively, these findings demonstrate the prospective role of SerpinB2 as a novel biomarker for acquired gefitinib resistance and a potential target for NSCLC treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To analyze the influence of the localization of mutations in the epidermal growth factor receptor (EGFR) gene on progression-free (PFS) and overall survival (OS) in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with gefitinib (gef) or chemotherapy (CT) under real world conditions within the REASON study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: P+G improved PFS compared with gefitinib alone in East Asian patients with advanced NS NSCLC and activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Blockage of celastrol-induced autophagic degradation of EGFR by autophagic inhibitor or calcium chelator decreased celastrol-mediated cell death in gefitinib-resistant NSCLCs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Overall, our findings suggest that celastrol may be developed as an effective anticancer agent for treatment of gefitinib-resistant NSCLC in the future. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, enhanced antitumor effect of AT-101, a-pan-Bcl-2 inhibitor, on gefitinib was explored in NSCLC with T790M mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The effect of cotreatment with AT-101 and gefitinib on the viability of NSCLC cell lines harboring acquired T790M mutation was investigated using the MTT assay. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The cellular apoptosis of NSCLC cells after cotreatment with AT-101 and gefitinib was assessed by FITC-annexin V/PI assay and Western blots analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: AT-101 enhances gefitinib sensitivity in NSCLC with EGFR T790M mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The addition of AT-101 to gefitinib is a promising strategy to overcome EGFR TKIs resistance in NSCLC with EGFR T790M mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We report a case of a patient with advanced NSCLC, in which oral gefitinib documented a significant antitumor effect on parallel progression of extracranial lesion and BM occurred during chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The novel therapy of gefitinib combined with radiofrequency hyperthermia is safe and effective for advanced NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We found that miR-26a was upregulated in gefitinib-refractory NSCLCs; miR-26a is downstream of EGFR signaling and directly targets and silences protein tyrosine phosphatase non-receptor type 13 (PTPN13) to maintain the activation of Src, a dephosphorylation substrate of PTPN13, thus reinforcing EGFR pathway in a regulatory circuit. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "miR-26a inhibition significantly improved NSCLC responses to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in non-small cell lung cancer (NSCLC) patients with drug-sensitive EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Importantly, we show here that the Src family inhibitor, dasatinib, dramatically inhibits cell adhesion-related response and greatly enhances the cell-killing effects of EGFR TKI (gefitinib for the PC9 cells; afatinib for the H1975 cells) in NSCLC cells, which would otherwise escape the TKI-induced apoptosis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we found that CsA significantly augmented the anti-cancer effect of gefitinib in EGFR-TKI-sensitive and -resistant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Hence, despite being the earliest EGFR TKI developed, gefitinib continues to be one of the first-line treatments for advanced EGFR-mutated NSCLC, especially when skin and gastrointestinal toxicity is a concern. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, the role of PAD4 in gefitinib\u2011acquired resistance in non-small cell lung cancer (NSCLC) remains unclear. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we aimed to investigate the role of PAD4 in the resistance of NSCLC to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The cells resistant to gefitinib were established in accordance with the literature, and were derived from NSCLC cell lines HCC827 and H1650. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Above all, our study showed that overexpression of PAD4 constrains the activity of EMT via suppressing Elk1 expression, and inhibits resistance of NSCLC to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our results suggest a therapeutic potential of Paris saponins in clinical settings for gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We aimed to examine genomic alterations associated with de novo resistance to gefitinib in a prospective study of NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Results: All 132 patients with EGFR mutation were treated with gefitinib for their treatment of advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the present study, we aimed to ascertain whether zoledronic acid (ZA) increases the antitumor effects of gefitinib treatment on NSCLC with EGFR mutations and the related mechanisms of action. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The effects of ZA and gefitinib on NSCLC tumor cells with EGFR mutations (HCC827, HCC827 GR and H1975) in regards to proliferation, apoptosis, cell cycle and signaling pathways were detected. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "ZA increased the antitumor effects of gefitinib on NSCLC with EGFR activating mutations and TKI resistance in\u00a0vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, ZA increased the antitumor effects of gefitinib on NSCLC with EGFR activating mutations and TKI resistance by regulating the cell cycle, inducing caspase-3\u00a0expression and inhibiting STAT3\u00a0expression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The combination of BO-1978 with gefitinib further suppressed EGFR mutant NSCLC cell growth in xenograft tumor and orthotopic lung tumor models. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, whether Ori can be used in gefitinib-resistant non-small cell lung cancer (NSCLC) cells remains unclear. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Results demonstrated that this compound dose-dependently inhibited the proliferation, invasion, and migration of the gefitinib-resistant NSCLC cells in\u00a0vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition, Ori upregulated protein phosphatase 2A (PP2A) activity of gefitinib-resistant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings indicated that Ori can inhibit the proliferation, invasion, and migration of gefitinib-resistant NSCLC cells by suppressing EGFR/ERK/MMP-12 and CIP2A/PP2A/Akt signaling pathways. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus, Ori may be a novel effective candidate to treat gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "During May 2008 to July 2013, 33 patients with Stage IV, EGFR mutation-positive non-small-cell lung cancer (NSCLC) were identified and received gefitinib (250 mg) as first line treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The median PFS was 8.9 months in Malaysian patients with EGFR mutation-positive NSCLC, treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, Malaysian patients with locally advanced and metastatic EGFR mutation-positive NSCLC responded favorably to gefitinib therapy in terms of ORR, median PFS, and tolerability, the results of which were consistent with those of the IPASS study conducted in an Asian population. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Considering the efficacy and safety profile of gefitinib, it is a favorable option for the first-line treatment of Malaysian patients with EGFR mutation-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Our objective is to compare the cost-utility of icotinib and gefitinib for the second-line treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The icotinib strategy, as a second-line therapy for advanced NSCLC patients in China, is the preferred strategy relative to gefitinib because of the dominant cost-utility. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Several recent studies have suggested that cancer stem cells (CSCs) are involved in resistance to gefitinib in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We previously reported that Oct4 and the putative lung CSC marker CD133 were highly expressed in gefitinib-resistant persisters (GRPs) in NSCLC cells, and GRPs exhibited characteristic features of the CSCs phenotype. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to elucidate the role of Oct4 in the resistance to gefitinib in NSCLC cells with an activating epidermal growth factor receptor (EGFR) mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSCLC cell lines, PC9, which express the EGFR exon 19 deletion mutation, were transplanted into NOG mice, and were treated with gefitinib in vivo. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Finally, immunohistochemical analysis revealed that Oct4 was highly expressed in tumor specimens of EGFR-mutant NSCLC patients with acquired resistance to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Collectively, these findings suggest that Oct4 plays a pivotal role in the maintenance of lung CSCs resistant to gefitinib in EGFR mutation-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The MET tyrosine kinase receptor and its ligand, hepatocyte growth factor (HGF), are known to be overexpressed in a variety of malignant tumor cells, and are implicated in the development of gefitinib-resistance in human non-small cell lung cancer (NSCLC) cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The approval was based on the results of a multicenter, single-arm, open-label clinical study of 106 treatment-na\u00efve patients with metastatic EGFR mutation-positive NSCLC who received gefitinib, 250 mg daily, until disease progression or intolerable toxicity. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: The outcome of 60 EGFR mutation-positive advanced NSCLC patients who received first-line gefitinib therapy (250 mg/d) was retrospectively analyzed according to EGFR mutation subtypes. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Clinical benefits of gefitinib administration in NSCLC patients have been observed in clinical practice, but the extent of the pulmonary toxicity of gefitinib in patients with advanced NSCLC remains unclear. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this systematic review was to evaluate the overall incidence and risk of gefitinib-related pulmonary toxicity in advanced NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated non-small cell lung cancer (NSCLC) resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We prospectively evaluated the association of pharmacokinetics and pharmacogenomics with the safety and efficacy of gefitinib in patients with EGFR mutation-positive advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings also confirm that first-line gefitinib is an active treatment option in Caucasians with EGFR mutation-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The US FDA has approved the kit for selecting patients with NSCLC for treatment with afatinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The clinical utility of the kit has been validated in phase 3 or 4 trials in which NSCLC patients with EGFR mutations as detected by the kit had greater clinical benefits with afatinib or gefitinib than with standard chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We investigated the therapeutic potential of ANT2 inhibition to EGFR-TKI resistance in NSCLC using gefitinib-sensitive (PC9 and HCC827) and gefitinib-resistant (H1975 and HCC827/GR) NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The present study aimed to explore the role of integrin \u03b21 and the relevant signaling pathways in acquired gefitinib resistance in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings suggest that integrin \u03b21 signaling via the PI3K/Akt pathway may be a significant mechanism underlying gefitinib resistance, and may potentially present an alternative therapeutic target for the treatment of NSCLC unresponsive to EGFR inhibitors. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Most of these analogues are comparable to gefitinib in their ability to inhibit non-small cell lung cancer (NSCLC) cell lines, and several also exhibited significantly enhanced anti-tumor potency. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We found that the combination of an ATM inhibitor, KU55933, and an EGFR-TKI, gefitinib, resulted in synergistic cell growth inhibition and induction of apoptosis in NSCLC cell lines carrying the sensitive EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "ATM inhibition may facilitate the gefitinib-dependent repression of the phosphorylation of EGFR and/or its downstream factors, to exert anticancer effects against NSCLC cells with the sensitive EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The study included 95 patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: The median PFS in patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment was 13.3 months (95% confidence interval 9.4-17.2). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: BMI and exon 19 mutation may be predictors of PFS in patients with EGFR mutation-positive advanced NSCLC who receive gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These LCSS outcomes provide further evidence that patients with wild-type EGFR might not benefit from first-line treatment of advanced NSCLC with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, a simple, rapid and credible high performance liquid chromatography-tandem mass spectrometry method was established and validated for the simultaneous quantification of gefitinib and its main metabolites M523595, M537194, M387783 and M608236 in NSCLC tumor-bearing mouse plasma. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small-cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Furthermore, nintedanib combined with gefitinib might be a novel therapeutic strategy for NSCLC cells with EMT phenotype and resistance to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Seven NSCLC patients harboring activating EGFR mutations who had developed LM during or after therapy with gefitinib, an EGFR TKI, were retrospectively analyzed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We examined the change in PD-L1 expression after gefitinib in patients with EGFR-mutant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "On the other hand, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, has been proved to be an efficient and safe strategy for treating NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC) patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Total Of 120 patients acquired gefitinib-resistance NSCLC patients treated in Taian City Central Hospital of Shandong province from May, 2010 to June, 2014 were incorporated in our study according to the inclusion and exclusion criteria. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The data demonstrated that knockdown of SphK2 led to decreased proliferation and enhanced chemosensitivity and apoptosis to gefitinib in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Inhibition of SphK2 might be considered as a strategy in NSCLC treatment with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the present study, the mitogen-activated protein kinase kinase 1/2 inhibitor, AZD6244, was used in combination with gefitinib to investigate the efficacy of this treatment in NSCLC cell lines, particularly in gefitinib-resistant cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The EGFR-TKI-sensitive PC-9 (mutant EGFR/wild-type K-Ras) and EGFR-TKI-resistant A549 (wild-type EGFR/mutant K-Ras) human NSCLC cell lines were treated with AZD6244 alone, gefitinib alone or the combination of the two drugs, and the effects were evaluated using cell proliferation assays, with alterations in signaling pathways analyzed by western blotting. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The data showed that the combination of AZD6244 and gefitinib exhibited dose-dependent synergism in gefitinib-resistant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus, a preclinical rationale exists for the use of AZD6244 to enhance the efficacy of gefitinib in patients with EGFR-TKI-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Although patients with non-small cell lung cancer (NSCLC) experience an initial response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib, those individuals with activating mutations in EGFR develop resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the present study, the therapeutic efficacy of gefitinib with GA was evaluated in a gefitinib-resistant NSCLC model. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The ability of miR-7 to enhance gefitinib-induced cytotoxicity in NSCLC cells was evaluated in this study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Furthermore, we examined the antitumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alterations and sensitivity to afatinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Recently, we have identified an effective analogue of resveratrol, (Z)3,4,5,4'-trans-tetramethoxystilbene (TMS) which selectively elevated the intracellular calcium level in gefitinib-resistant (G-R) non-small-cell lung cancer (NSCLC) cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "AIM: The present study, performed in a panel of NSCLC cell lines expressing different ABCG2 plasma membrane levels, was designed to investigate the effect of the efflux transporter ABCG2 on intracellular gefitinib accumulation, by dissecting the contribution of uptake and efflux processes. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The sensitivity of NSCLC cells to gefitinib was restored after treatment with the s-9R/siRNA complex, and the apoptosis rates of the treated cells were significantly higher than those of the control groups. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Several EGFR tyrosine kinase inhibitors(TKIs), such as gefitinib, have been used as effective clinical therapies for patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "244-MPT could also induce apoptosis in a gefitinib-resistant cell line and strongly suppress gefitinib-resistant NSCLC tumor growth in a xenograft mouse model. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition, 244-MPT could effectively reduce the size of tumors in a gefitinib-resistant NSCLC patient-derived xenograft (PDX) SCID mouse model. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients, who were \u2265 18 years, chemona\u00efve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Results from another large-scale randomized trial (ARCHER 1050) comparing dacomitinib to gefitinib as first-line treatment of advanced treatment-na\u00efve EGFR-mutant NSCLC patients will soon be available and will serve as the lynchpin trial for the potential approval of dacomitinib in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Knocking-down of CTSL in PC-9/GR cells could decrease cell proliferation and potentiate apoptosis induced by gefitinib, suggesting CTSL may contribute to gefitinib resistance in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subsequently, gefitinib was combined with celecoxib to investigate the efficacy of inhibition in vitro in two NSCLC cell lines: HCC827 (del E746-A750) and A549 (wild-type EGFR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study demonstrates that high serum COX-2 levels may indicate EGFR mutations and that the efficacy of combined celecoxib and gefitinib is significantly greater in NSCLC cells with EGFR mutations; at high concentrations, the combination is efficacious in wild-type NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "With the developed assay, we found that the intracellular accumulations of berberine in two gefitinib resistant NSCLC cell lines H1650 and H1975 were 2-3 folds higher than that of normal epithelial cells BEAS-2B. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) T790M mutant is found in approximately 50% of clinically acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " In non-small-cell lung cancer (NSCLC) patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition, Gremlin silencing significantly potentiated apoptosis induced by gefitinib in PC-9/GR with Gremlin knockdown compared to PC-9 transfected with control shRNA, suggesting Gremlin contributes to gefitinib resistance in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSCLC cell lines and nude mice were used to study the treatment reactivity of gefitinib (an EGFR inhibitor) with or without 5-aza-2'-deoxycytidine (5-aza-CdR) intervention. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The purpose of this study was to evaluate the impact of smoking status on the efficacy of gefitinib in patients with NSCLC harboring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib at Kitasato University Hospital were retrospectively reviewed, and the treatment outcomes were evaluated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The clinical data obtained in this study provide a valuable rationale for considering smoking status as a predictor of the efficacy of gefitinib in patients with NSCLC harboring activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Radiation-naive NSCLC patients with BM were enrolled and treated with gefitinib for 2 weeks, and then concurrently combined with WBRT for 2 weeks. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The WBRT may not affect the BBB permeability by determining the concentration of gefitinib in NSCLC patients with BM. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results provide useful diagnostic markers and therapeutic candidates for treating gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: The combination use of gefitinib and epidermal growth factor receptor (EGFR) testing is a standard first-line therapy for patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR mutation has not been elucidated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, the objective of this study was to investigate the efficacy and feasibility of gefitinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We retrospectively evaluated the clinical effects of gefitinib as a first-line treatment for elderly (\u226575 years) NSCLC patients with EGFR mutations (exon 19 deletion or exon 21 L858R mutation). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: First-line gefitinib could be a preferable standard treatment in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We report a case in which a male patient with advanced non-small cell lung cancer (NSCLC) developed repetitive pneumothorax after receiving a combination of the chemotherapeutic drugs gefitinib and amrubicin (GEF\u00a0+\u00a0AMR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Docetaxel and gefitinib play key roles in the treatment of non-small-cell lung cancer (NSCLC), and their combination could be of interest. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " There is no consensus on the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC) and stable disease (SD) after gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This randomized, open-label, multicenter study aimed to explore whether dose-escalation of gefitinib would improve response and survival in NSCLC patients who achieved SD after one-month of standard gefitinib dosage. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This is the first randomized clinical trial that showed a significant and clinical meaningful OS benefit in EGFR mutation-positive NSCLC patients following maintenance therapy with gefitinib as compared to placebo. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Then, two gefitinib-resistant (GR) NSCLC cell lines, HCC827 GR and PC9 GR, from their parental cells were established. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Specifically, inhibition of the constitutive activation of PI3K/Akt pathway substantially suppressed Cx26 expression, and Cx26 was confirmed to functionally interplay with PI3K/Akt signaling to promote EMT and gefitinib resistance in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, the reciprocal positive regulation between Cx26 and PI3K/Akt signaling contributes to acquired gefitinib resistance in NSCLC cells by promoting EMT via a GJIC-independent manner. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: The purpose of this study was to evaluate the predictive role of quantitative metabolic parameters using total lesion glycolysis (TLG) in F-2-fluoro-2-deoxyglucose-positron emission tomography/computed tomography for developing gefitinib resistance in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients treated with first-line gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A total of 75 NSCLC patients harboring activating EGFR mutation and receiving first-line gefitinib were analyzed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: TLG can predict PFS and development of gefitinib resistance in EGFR-mutant NSCLC patients treated with first-line gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Moreover, in NSCLC cell lines that are resistant to gefitinib, a drug often used in TKI therapies to treat NSCLC, miR-200a expression is able to render the cells much more sensitive to the drug treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2015.07.11 PMID: 26182873 [PubMed - indexed for MEDLINE]  miRNA expression is deregulated in non-small cell lung cancer (NSCLC), and some miRNAs are associated with gefitinib sensitivity. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "A retrospective study was conducted to investigate the associations of the pretreatment serum pro-gastrin-releasing peptide (pro-GRP) and plasma neuron-specific enolase (NSE) levels to the patient survival rate following initiation of treatment with gefitinib in non-small cell lung cancer (NSCLC) patients receiving gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients with NSCLC harboring EGFR gene mutations who received gefitinib therapy between 2004 and 2012 were included in the study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results suggest that pretreatment NSE measurement could be clinically useful in patients with NSCLC scheduled to receive gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The present study reports a case of NSCLC with EGFR mutation (exon 19 deletion) in which dose-reduced gefitinib was effective against recurrence. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The patient has been in remission for 27 months since treatment with 250 mg gefitinib once every 3 days was initiated, which is the lowest dose to be reported in a successfully treated case of NSCLC with EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, the mutation status of EGFR was assessed in advanced-stage NSCLC patients to determine how mutation status influences the clinical efficacy of gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The study included 106 patients with advanced NSCLC who were treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The findings indicate that gefitinib treatment can improve the clinical outcomes of NSCLC patients with EGFR mutation, prolonging their survival time with only mild adverse events. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage non-small cell lung cancer (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Moreover, gefitinib resistance was reversed by a combination treatment with gefitinib and fulvestrant, both in cell lines and in one NSCLC patient. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in non-small cell lung cancer (NSCLC) cell lines with the rationale of potentially translating these findings into the clinical setting. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Patients with brain metastases from NSCLC receiving GK or gefitinib demonstrated extended survival. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Prospective cohort data from 115 NSCLC patients with EGFR-mutant tumours, who received gefitinib monotherapy between 2007 and 2012, were analysed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: We found in the prospective cohort data that BSA could affect the efficacy of gefitinib monotherapy in patients with EGFR-mutant NSCLC, suggesting that BSA-based dose setting of gefitinib monotherapy might be further investigated, despite the fact that no molecular-targeted agent described to date undergoes dose adjustment according to BSA. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The EGFR-TKI gefitinib can reduce PD-L1 expression, via inhibiting NF-\u03baB, in EGFR mutant NSCLC in\u00a0vitro and in\u00a0vivo. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS/PATIENTS: We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our previous in vitro results showed that Marsdenia tenacissima extract (MTE) overcomes gefitinib resistance in non-small cell lung cancer (NSCLC) cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The present results suggest that the combination of MTE and gefitinib may be a promising therapeutic approach to enhance gefitinib efficacy in resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor (EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this trial was to evaluate the efficacy and toxicity of gefitinib in NSCLC patients with WT EGFR who failed previous chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Small proportion of NSCLC patients with the WT EGFR benefits with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus FZKA granules) or control group (gefitinib plus placebo). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to non-small cell lung cancer (NSCLC) patients has been limited due to emergence of acquired drug resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The anticancer effect of USP8 inhibitor was determined by testing anchorage-dependent or independent growth of gefitinib-sensitive or resistant NSCLCs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Inhibition of USP8 induced overall degradation of oncogenic receptor tyrosine kinases including EGFR and Met, leading to a suppression of anchorage-dependent or independent cell growth of gefitinib-sensitive or resistant NSCLCs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Inhibition of USP8 could be an effective strategy for overcoming gefitinib resistance in NSCLCs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our data suggest that inhibition of autophagy may be a therapeutic strategy to overcome acquired resistance of gefitinib in EGFR mutation NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The specimens were obtained from patients treated with gefitinib as 1st-, 2nd-, or 3rd-line therapy for postoperative recurrent NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, NSCLC with exon 20 mutation may respond to gefitinib treatment in the presence of an additional EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC harboring EGFR mutations or prior systemic response to EGFR-TKI. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Although the MTD was not defined due to slow accrual, this study provides important information about the tolerability and CSF penetration of high-dose gefitinib as a therapeutic option for modest palliation for NSCLC patients with LM and a known EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To evaluate the EGFR mutations in non small cell lung cancer (NSCLC) patients in Bulgaria, as well as to summarize the outcomes of patients with EGFR mutations, treated with gefitinib as first- or subsequent-line therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our data give grounds for the conclusion that gefitinib is an effective and well-tolerated therapeutic option for patients with locally advanced and metastatic NSCLC harboring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, remains a major problem in non-small cell lung cancer (NSCLC) treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Based on the findings, we attempted to enhance AXL degradation to overcome acquired gefitinib-resistance by the treatment of gefitinib-resistant NSCLC cells with yuanhuadine (YD), a potent antitumor agent in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we developed a gefitinib-resistant cell subline (PC-9-GR) with a secondary EGFR mutation (T790M) from NSCLC PC-9 cells after chronic exposures to increasing doses of gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Moreover, the association between the smoking status and the progression-free survival (PFS) period was investigated in patients with EGFR-mutated NSCLC who were treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Eight patients diagnosed with non-small cell lung cancer (NSCLC) (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, the role of ERK1/2 and AKT-mediated XRCC1 expression in gefitinib alone or combination with an Hsp90 inhibitor-induced cytotoxicity in non-small cell lung cancer (NSCLC) cells has not been identified. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, gefitinib treatment decreased XRCC1 mRNA and protein expression through ERK1/2 and AKT inactivation in two NSCLC cells, A549 and H1975. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Compared to a single agent alone, gefitinib combined with an Hsp90 inhibitor resulted in cytotoxicity and cell growth inhibition synergistically in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings suggested that down-regulation of XRCC1 can enhance the sensitivity of gefitinib for NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We reported recently that an aberration in certain steps of EGF-stimulated phosphorylated epidermal growth factor receptor (pEGFR) endocytic trafficking from the early endosomes to the late endosomes occurs in the gefitinib-resistant NSCLC cells, in which large amounts of sorting nexin 1 (SNX1) are colocalized with EGFR in the aggregated early endosomes where the internalized pEGFR is also accumulated of these cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Large phase III or IV clinical trials in patients with locally advanced or metastatic NSCLC showed that gefitinib as first- or subsequent-line treatment significantly prolonged progression-free survival (PFS) and improved objective response rates and/or health-related quality of life parameters in patients with activating EGFR mutations and in clinically selected patients (e.g., Asian patients or never-smokers) who are more likely to harbour these mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Although the position of gefitinib with respect to other EGFR TKIs is not definitively established, current evidence indicates that gefitinib monotherapy is an effective and generally well-tolerated first- or subsequent-line treatment option for patients with NSCLC and activating EGFR mutations who have not received an EGFR TKI previously. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We used HCC827 and PC-9, which are NSCLC cell lines harboring EGFR exon 19 deletions, and gefitinib-resistant sublines derived from the same cell lines with T790M mutation, MET amplification or stem-cell like properties. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients with NSCLC with EGFR-activating mutation benefit greatly by gefitinib, an EGFR tyrosine kinase inhibitor. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Gefitinib-resistant NSCLC cells showed HDAC1 overexpression, and its knockdown sensitized resistant cells to gefitinib in vitro and in preclinical models through DUSP1 expression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to determine the response of advanced-stage non-small cell lung cancer (NSCLC) patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results indicate that patients with advanced-stage NSCLC with EGFR mutations have a\u00a0better response to chemotherapy followed by gefitinib than chemotherapy alone and a\u00a0better response to chemotherapy than wild-type patients.KEYWORDS: chemotherapy, gefitinib, NSCLC, tyrosine kinase inhibitors. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations within the kinase domain of EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We analyzed 31 Japanese patients with non-small-cell lung cancer (NSCLC) who had been treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We performed a phase I/II study combining gefitinib with vorinostat in previously treated non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, this combination showed a potential for improving efficacy of gefitinib in EGFR-mutant NSCLC (NCT01027676). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with advanced non-small-cell lung cancer without disease progression after first-line chemotherapy, were published previously. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "She underwent chemotherapy with gefitinib (Iressa\u2122) for NSCLC and gamma knife surgery for multiple brain metastases. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we aimed to identify partner drugs and pathways that can induce cell death in combination with gefitinib in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Firstly, we identified PRKCSH as a candidate gene, silencing of which induces apoptosis of NSCLC cells treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We showed that the combination of dasatinib (NF-\u03baB pathway inhibitor) with gefitinib synergistically inhibited the growth of NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In our experiments, it synergized with gefitinib to reduce p-Akt levels and to induce apoptosis in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Taken together, a pooled short-hairpin library screen identified several potential pathways and drugs that can be therapeutic targets for gefitinib resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Our results suggest that gefitinib use in patients with NSCLC and poor PS may improve the QOL of older patients and African American patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " We report the long-term outcome of 4 patients who underwent pulmonary resection for residual or regrown primary lesion of non-small cell lung cancer (NSCLC) treated with a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Erlotinib and gefitinib are among the most widely researched, used and available molecularly targeted therapies for treatment of advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to systematically evaluate the efficacy and safety of gefitinib and cetuximab-based therapies in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The studies to be used for the comparisons were selected from the available literature on gefitinib and cetuximab-based therapies compared to conventional chemotherapy in patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "As regards efficacy, the risk ratio (RR) of objective response rate and 1-year survival rate between gefitinib and cetuximab-based therapies in patients with advanced NSCLC were 0.99 [95% confidence interval (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, and the mean difference of progression-free survival and overall survival (OS) were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; P=0.0331), respectively. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results demonstrated that cetuximab-based therapy was superior to gefitinib therapy in terms of OS and inferior to gefitinib therapy in terms of AEs, whereas there were no significant differences in terms of efficacy and safety between the two therapies on other endpoints adopted for advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Some patients with non-small-cell lung cancer (NSCLC) respond well to the EGFR tyrosine kinase inhibitor gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We aim to determine whether gefitinib plus CHM could prolong the progression-free survival (PFS) or median survival time (MST) in patients with NSCLC than gefitinib alone. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: This case-control analysis suggested that treatment with gefitinib plus CHM prolonged PFS and MST compared with gefitinib in patients with NSCLC, and it is worthy of further study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to evaluate the usefulness of MUC1 and vascular endothelial growth factor (VEGF) mRNA expression in peripheral blood as means of predicting benefit from gefitinib therapy in NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: MUC1 and VEGF mRNA expressions were detected in peripheral blood of 66 patients with advanced NSCLC before (B0) and 4 weeks after treatment (B4w) with gefitinib, using real-time quantitative-PCR assay. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: MUC1 and VEGF mRNA positivity in blood seem to be indicators of unfavorable response and poor PFS and OS in patients with advanced NSCLC treated with gefitinib and may be promising noninvasive and repeatable markers for predicting efficacy of gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Currently, the epidermal growth factor receptor inhibitor gefitinib is widely used for patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the present work, four NSCLC cell lines (H1299, A549, PC-9, and PC-9/AB11) with different sensitivities to gefitinib were subjected to analysis of the expression of Mig-6. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We found that Mig-6 is over-expressed in gefitinib-sensitive NSCLC cell lines, but is low in gefitinib-resistant NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Further analysis revealed that over-expression of Mig-6 increased cell apoptosis and inhibited proliferation of gefitinib-resistant NSCLC cells treated with gefitinib, whereas lowering the expression of Mig-6 decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in gefitinib-sensitive NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that Mig-6 is involved in mediating the response to gefitinib in NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Additionally we demonstrated that Mig-6 could reverse gefitinib resistance through inhibition of EGFR/ERK pathway in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, first-line gefitinib should not be recommended for advanced non-small cell lung cancer (NSCLC) patients only based on clinical factors, due to a very small sample-size in our study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Development of molecular targeting agents, starting with imatinib for chronic myeloid leukemia or gefitinib for non-small cell lung cancer (NSCLC), has recently progressed at a rapid rate. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutations in the epidermal growth factor receptor (EGFR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We retrospectively reviewed the medical records of consecutive patients with postoperative recurrent NSCLC (postoperative group) or stage IV NSCLC (stage IV group) harboring EGFR mutations who were treated with gefitinib at the Shizuoka Cancer Center between September 2002 and March 2012 to compare the effect of gefitinib on survival from treatment initiation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: PFS and OS were superior in patients with postoperative recurrent NSCLC harboring EGFR mutations treated by gefitinib than in those with stage IV disease. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here we show miR-200c overexpression was correlated with the epithelial phenotype and sensitivity to gefitinib in EGFR wild-type NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "From September, 2003, to November, 2006, 70 consecutive patients with advanced, progressive NSCLC, previously treated with chemotherapy, received oral gefitinib 250 mg daily. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this consecutive, non-randomized, series of advanced NSCLC patients, the use of IL-2 increased the efficacy of gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients, and this led to the approval of icotinib for NSCLC by the China Food and Drug Administration. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The discovery of epidermal growth factor receptor (EGFR) mutations in NSCLC in 2004 and the marked response to the EGFR tyrosine kinase inhibitor gefitinib, in a small subset of patients harboring these genetic abnormalities, stimulated the study of other kinase mutants involvement in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The IRENE (Iressa RE-challenge in advanced, EGFR-mutated NSCLC patients who responded to an EGFR-TKI used as first-line or previous treatment) (Dutch association for pulmonologists [NVALT]-16) trial is a multicenter, open-label, single-arm, single-stage, phase II study to evaluate gefitinib rechallenge in EGFR-mutated NSCLC patients who were previously treated with a TKI followed by a subsequent line of treatment (excluding EGFR-TKIs). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: The IRENE (NVALT-16) trial will evaluate the safety, efficacy, and feasibility of readministration of gefitinib after an EGFR-TKI-free interval in EGFR-mutated NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The study will evaluate gefitinib re-challenge in EGFR-mutated NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: EGFR gene typing in 33 advanced NSCLC patients received gefitinib (250 mg/day) were analyzed with mutant-enriched PCR assay. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: EGFR mutated gene and non-smoker status are potential predictors for gefitinib response in NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "It has been found that treatment with gefitinib induces cell cycle arrest and apoptosis in NSCLC cells harboring activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We used the gefitinib-sensitive NSCLC cell line HCC827, which harbors a deletion in exon 19 of the EGFR gene, to examine the effect of gefitinib on the apoptotic machinery. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: We found that gefitinib treatment caused the NSCLC cells to undergo apoptosis following activation of the caspase 8 cascade. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Based on our results, we conclude that gefitinib-induced apoptosis is mediated by the interaction of p27 and caspase 8 in NSCLC cells carrying an activating EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Twenty-five NSCLC patients with epidermal growth factor receptor (EGFR) mutation were initially treated with gefitinib (250 mg/day). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus, in the present study, we investigated overcoming resistance against the TKI gefitinib by combination treatment with melatonin in H1975 NSCLC cells harbouring the T790M somatic mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Exon 19 deletions and L858R point mutation are the most commonly encountered active epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and they predict greater efficacy of gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The objective of this study was to evaluate whether body surface area (BSA) affects the efficacy of gefitinib in patients with NSCLC harboring an active EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We reviewed the medical records of consecutive patients with advanced NSCLC harboring an active EGFR mutation who received gefitinib monotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The efficacy of gefitinib in patients with NSCLC harboring an EGFR mutation does not differ according to their BSA. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The candidate with the highest affinity, H2, was radiolabeled with (89)Zr for immunoPET studies targeting NSCLC xenografts: low MET-expressing Hcc827 and the gefitinib-resistant Hcc827-GR6 with 4-fold MET overexpression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The receptor tyrosine kinase inhibitors such as gefitinib are not perfect clinical therapeutic agents for NSCLC treatment due to primary or acquired tyrosine kinase inhibitor resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "36245-PHF was shown to inhibit PI3K and Aurora A and B kinases and overcome gefitinib-resistant NSCLC growth. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our data clearly showed that 36245-PHF markedly inhibited anchorage-independent growth of gefitinib-resistant NSCLC cell lines and exerted a substantial chemotherapeutic effect following oral administration in a gefitinib-resistant NSCLC xenograft model. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Overall, we identified 36245-PHF as a multiple protein kinase inhibitor and as a novel therapeutic agent to overcome gefitinib-resistant NSCLC growth, which could provide a new option for clinical NSCLC oral treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study reports an EGFR mutation in NSCLC treated with gefitinib and is notable due to the patient's marked improvement following a shorter than average duration of treatment with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we have examined the anticancer effects of WK88-1 in Met-amplified- and gefitinib-resistant (HCC827GR) NSCLC cells and its parental HCC827 cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, we demonstrate that inhibition of Hsp90 dampens the activation of EGFR- or c-Met-mediated survival of Met-amplified NSCLCs and that WK88-1 as a Hsp90 inhibitor alleviates gefitinib resistance in HCC827GR cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In 2004, activating mutations in the EGFR gene were discovered to be a predictive biomarker for EGFR-TKI treatment, and gefitinib, which is not effective for patients with EGFR wild-type NSCLC, has since been used only in patients with EGFR-mutated NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Some individuals with non-small-cell lung cancer (NSCLC) benefit from therapies targeting epidermal growth factor receptor (EGFR), and the characterization of a new mechanism of resistance to the EGFR-specific antibody gefitinib will provide valuable insight into how therapeutic strategies might be designed to overcome this particular resistance mechanism. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Although first-line gefitinib is one of the standard treatments for advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, few data have been reported regarding gefitinib and elderly patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients aged 70 years or older with stage IIIB or IV NSCLC harboring EGFR-activating mutation were enrolled and treated with 250 mg of gefitinib daily until disease progression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: It has previously been shown that gefitinib-treated patients with epidermal growth factor receptor (EGFR) gene amplification or high polysomy had a statistically significant improvement in response, time to progression, and survival in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our findings provide a new basis for using miR 21/Pten-based therapeutic strategies to reverse gefitinib resistance in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We retrospectively analyzed 35 patients with advanced NSCLC treated with first-line gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Exon 19 deletion and L858R point mutation of the epidermal growth factor receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell lung cancer (NSCLC), and predict higher clinical outcomes following treatment with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The objective of this study was to evaluate the differential clinical outcomes of gefitinib in patients with NSCLC according to the type of active EGFR mutation, i.e. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We identified patients with advanced NSCLC harboring the exon 19 deletion or the L858R point mutation of EGFR who were on gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: It may be considered that there is no difference in the clinical efficacy of gefitinib between NSCLC patients who harbor the exon 19 deletion and those with the L858R point mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The clinical efficacy of gefitinib in the treatment of non-small cell lung cancer (NSCLC) with mutations in exon 18, 19 or 21 of epidermal growth factor receptor (EGFR) is limited by the acquired resistance to the drug. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "To explore whether X-ray irradiation could reverse the acquired gefitinib resistance in NSCLC cell in vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We chose a human NSCLC cell line NCI-H1975 to establish acquired gefitinib-resistant cell line named as NCI-H1975/GR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results indicated that the acquired gefitinib resistance could be reversed by X-ray irradiation in NSCLC cell line NCI-H1975 harboring both the L858R and T790M mutation in vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The patients experiencing gefitinib dose reduction or short-term treatment interruption due to toxicities did not show inferior survival, compared to those receiving full dose of gefitinib in NSCLC patients with EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study demonstrates for the first time that miR-34a rescues HGF-induced gefitinib resistance in EGFR mutant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We hypothesized that butein, a phytochemical, can overcome gefitinib-induced resistance by targeting both EGFR and MET in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The effects of butein on growth, induction of apoptosis and expression of EGFR/MET signaling targets were examined in HCC827 (gefitinib-sensitive) and HCC827GR (gefitinib-resistant) NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To investigate the effects of autophagy on growth inhibition by gefitinib in non-small cell lung cancer (NSCLC) cell lines and its probable mechanism. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This obstructive atelectasis interrupted the evaluation of efficacy of the subsequent gefitinib treatment for non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, it is crucial to accurately determine the cause of late complications in NSCLC patients receiving sequential SBRT and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Herein we describe a case, at our knowledge the first reported, of a patient with advanced lung adenocarcinoma on maintenance hemodialysis treated with gefitinib and then with afatinib; we also reviewed the literature on epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) used in NSCLC patients with concomitant renal impairment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this review, we summarize the current data from clinical trials with gefitinib and appraise its role in the management of locally advanced or metastatic NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: In this study we investigated the effect of T-DM1 in a panel of NSCLC cell lines with different HER-2 expression levels, in H1781 cell line carrying HER-2 mutation and in gefitinib resistant HER-2 overexpressing PC9/HER2cl1 cell clone. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, most of NSCLC patients are with wild type EGFR, and showed limited response to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our previous study showed Marsdenia tenacissima extract (MTE) restored gefitinib efficacy in the resistant NSCLC cells, but whether MTE acts in the gefitinib-sensitive NSCLC cells is the same as it in the resistant one is unknown. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Dose response curves for gefitinib and MTE were generated for two sensitive NSCLC cell lines with mutant or wild type EGFR status. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Unlike in the resistant NSCLC cells, our results revealed that low cytotoxic dose of MTE (8 mg/ml) combined gefitinib with three different schedules synergistically or additively enhanced the growth inhibition of gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MTE markedly prompted cell cycle arrest and apoptosis caused by gefitinib both in EGFR mutant (HCC827) and wild type of NSCLC cells (H292). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Unlike in gefitinib-resistant NSCLC cells, MTE alone also demonstrated certain unexpected modulation on EGFR related cell signal pathways in the sensitive cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Our results suggest that MTE is a promising herbal medicine to improve gefitinib efficacy in NSCLC regardless of EGFR status. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, why MTE acted differently between gefitinib-sensitive and -resistant NSCLC cells needs a further research. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), including gefitinib, provide a significant clinical benefit in non-small-cell lung cancer (NSCLC) patients, the acquisition of drug resistance has been known to limit the efficacy of EGFR-TKI therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Importantly, the RAC1 inhibition suppressed EGFR-mutant NSCLC cell migration and growth in\u00a0vitro, and growth in\u00a0vivo even in the gefitinib-resistant cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib, have shown promising therapeutic efficacy in nonsmall cell lung cancer (NSCLC) patients harboring EGFR activating mutation, development of acquired resistance is almost inevitable. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We investigated whether the addition of Epimedium koreanum Nakai extract (EEF) to gefitinib could overcome the resistance of NSCLC cells to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: In this study, we analyzed the protein level of Dicer between gefitinib-sensitive (PC9) and gefitinib-resistant (PC9/GR) non-small-cell lung cancer (NSCLC) cell lines by Western blot analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Silencing of Dicer induces sensitivity to gefitinib in NSCLC cells through the downregulation of miR-30b/c and miR-221/222 to increase the protein level of caspase-3, resulting in an increase in gefitinib-induced apoptosis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of the present study was to evaluate the effects of Paris saponin I (PSI) on a panel of gefitinib-resistant NSCLC cell lines and its inhibition of tumor growth in a nude mouse model. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Between January 2008 and September 2009, we enrolled 50 patients with advanced NSCLC who had received one or more chemotherapy regimens, including gefitinib monotherapy to which they had partial responses (PR) or stable disease (SD). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to explore the clinical characteristics of and treatment strategies for interstitial pneumonia induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The detailed clinical data of one patient with NSCLC and gefitinib-induced interstitial pneumonia were compiled and a review of relevant previous studies was performed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Although among these activities, its anti-cancer effects have attracted the most attention, the effect of celastrol on gefitinib-resistant non-small cell lung cancer (NSCLC) cells is not clearly known. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We explored its treatment mechanism in two gefitinib-resistant NSCLC cell lines (H1650 and H1975). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Taken together, our data showed that celastrol may be developed as a promising agent for treating gefitinib-resistant NSCLCs by inducing apoptosis through caspase-dependent pathways and Hsp90 client protein degradation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Although non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We demonstrated that addition of simvastatin to gefitinib enhanced caspase-dependent apoptosis in T790M mutant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "To determine the role of survivin in simvastatin-induced apoptosis of gefitinib-resistant NSCLC, we showed that the proportion of apoptotic cells following treatment with survivin siRNA and the gefitinib-simvastatin combination was greater than the theoretical additive effects, whereas survivin up-regulation could confer protection against gefitinib and simvastatin-induced apoptosis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Use of EGFR inhibitory agents such as gefitinib for this subset of NSCLC patients causes tumor regression and disease stabilization for 12-18 mo, after which tumor cells become resistant to the drug. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Herein, we investigated anti-tumor effects of the combination of BGT226, a novel PI3K/mTOR dual inhibitor, and gefitinib on NSCLC cell lines which are high sensitive to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: In non-small cell lung cancer (NSCLC) cell lines with activating EGFR mutations (PC9 or HCC827), gefitinib treatment markedly reduced pEGFR, pAKT, and pMAPK levels and was associated with an increase in cleaved PARP but not in \u03b3H2AX foci. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In contrast, NSCLC cell lines with EGFR T790M (H1975) or wild-type EGFR (A549) were insensitive to gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Recently, miRNAs such as miR-130a have been shown to play a role in gefitinib resistance, but importance in NSCLC and relationships with Met have not been fully explored. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here we show that miR-130a is over-expressed in gefitinib- sensitive NSCLC cell lines, but is low in gefitinib-resistant NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Further analysis revealed that over-expression of miR-130a increased cell apoptosis and inhibited proliferation of NSCLC cells treated with gefitinib, whereas lowering the expression of miR-130a decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in both gefitinib-sensitive and -resistant NSCLC cell lines, suggesting that miR-130a overcomes gefitinib resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings indicate that the miR-130a/Met axis plays an important role in gefitinib resistance in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Maintenance gefitinib significantly prolonged progression-free survival (PFS) compared with placebo in patients from eastern Asian with locally advanced/metastatic non-small-cell lung cancer (NSCLC) after four chemotherapeutic cycles (21 days per cycle) of first-line platinum-based combination chemotherapy without disease progression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The administration of gefitinib following PC adjuvant therapy shows significant improvement in DFS in patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as gefitinib are clinically effective treatments for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We established a gefitinib-resistant cell model (PC9GR) by continually exposing PC9 NSCLC cells to gefitinib for 6 months. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Re-expression of miR-138-5p was sufficient to sensitize PC9GR cells and another gefitinib-resistant NSCLC cell line, H1975, to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Collectively, our results suggest that downregulation of miR-138-5p contributes to gefitinib resistance and that restoration of miR-138-5p or inhibition GPR124 might serve as potential therapeutic approach for overcoming NSCLC gefitinib resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, in patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we investigated the clinical significance of immunoglobulin G (IgG) responses to EGFR-derived peptides in NSCLC patients receiving gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Plasma IgG titers to each of 60 different EGFR-derived 20-mer peptides were measured by the Luminex system in 42 NSCLC patients receiving gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Detection of IgG responses to EGFR-derived peptides may be a promising method for prognostication of NSCLC patients receiving gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NTS stimulates whereas SR48692 or gefitinib inhibits the clonal growth of NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our aim here was to elucidate the role of hypoxia and CSCs in the resistance to gefitinib in non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSCLC cell lines, PC9 and HCC827, which express the EGFR exon 19 deletion mutations, were exposed to high concentration of gefitinib under normoxic or hypoxic conditions. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Collectively, these findings suggest that hypoxia increased the population of lung CSCs resistant to gefitinib in EGFR mutation-positive NSCLC by activating IGF1R. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Targeting the IGF1R pathway may be a promising strategy for overcoming gefitinib resistance in EGFR mutation-positive NSCLC induced by lung CSCs and microenvironment factors such as tumor hypoxia. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we show that integrin\u03b21 induced epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in xenograft tumors and gefitinib-resistant NSCLC tumors acquired EMT phenotype. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we report a case of ALP flare following gefitinib treatment for NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Herein we investigated clinical characteristics of NSCLC patients who experienced acquired resistance during gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: We reviewed NSCLC patients who showed a clinical benefit from initial gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition, subsequent chemotherapy confers clinical benefit in terms of PPS in NSCLC patients who experienced acquired resistance after gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition, several large phase III clinical trials (e.g., INFORM trial) provided evidence that maintenance therapy with gefitinib also significantly improved PFS in NSCLC patients, with greatest PFS benefit in patients harboring EGF-R mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In our previous study, we found that combined treatment with fulvestrant and gefitinib decreases the proliferation of H1975 NSCLC cells, compared to treatment with either fulvestrant or gefitinib alone; however, the molecular mechanism for the improved effects of the combination treatment are still unknown. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We retrospectively reviewed 81 advanced NSCLC patients with disease progression following tumor response and durable (\u2265 6 months) disease stabilization with first-line or second-line gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: First-line gefitinib was effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell lung cancer (NSCLC) because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The phase II NEJ001 trial suggested that gefitinib was active against advanced non-small cell lung cancer (NSCLC) even in patients with poor performance status (PS). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study has retrospectively investigated the clinical outcomes of gefitinib treated patients with advanced NSCLC, EGFR mutations, and poor PS. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: A total of 208 patients with advanced NSCLC and poor PS treated with gefitinib from 2004 to 2013 were retrospectively evaluated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Fifty-two patients (25.0%) with advanced NSCLC, EGFR mutation, and poor PS were treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Patients with advanced NSCLC, EGFR mutation, and poor PS have poor outcomes in response to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The Iressa Alliance program provided standardized EGFR mutation testing and appropriate access to gefitinib to all patients in British Columbia with advanced, non squamous non small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, we evaluated the molecular mechanisms supporting the therapeutic potential of gefitinib maintenance in the HCC827 GR5 NSCLC cell line harbouring MET amplification as acquired resistance mechanism. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our previous study showed that Marsdenia tenacissima extract (MTE) restored gefitinib sensitivity in gefitinib-resistant non-small cell lung cancer (NSCLC) cells, but the mechanism involved is unknown. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and epidermal growth factor receptor (EGFR) mutation affect the prescribing patterns and clinical outcomes of treatment with gefitinib in NSCLC, in a real practical field. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We conducted a retrospective analysis of the consecutive database of NSCLC patients who were treated with gefitinib at Seoul National University Hospital between January 2002 and December 2011. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: A total of 1,115 NSCLC patients, who received gefitinib at recurred or metastatic setting, were included in this study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Publisher: \u76ee\u524d\uff0c\u80ba\u764c\u662f\u5168\u4e16\u754c\u8303\u56f4\u5185\u53d1\u75c5\u7387\u548c\u6b7b\u4ea1\u7387\u6700\u9ad8\u7684\u6076\u6027\u80bf\u7624\uff0c\u5176\u4e2d\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u5360\u5168\u90e8\u80ba\u764c\u768480%\u5de6\u53f3\uff0c\u800cNSCLC\u60a3\u8005\u4e2d\u6709\u5f88\u5927\u4e00\u90e8\u5206\u5728\u786e\u8bca\u65f6\u5df2\u7ecf\u5904\u4e8e\u665a\u671f\u3002\u56e0\u6b64\uff0c\u5bf9\u4e8e\u665a\u671fNSCLC\u7684\u6cbb\u7597\u4e5f\u8d8a\u6765\u8d8a\u53d7\u5230\u4eba\u4eec\u7684\u91cd\u89c6\u3002\u867d\u7136\u665a\u671fNSCLC\u7684 \u6807\u51c6\u6cbb\u7597\u4e3a\u542b\u94c2\u53cc\u836f\u8054\u5408\u5316\u7597\uff0c\u4f46\u662f\u5316\u7597\u836f\u7269\u5bf9\u6539\u5584\u665a\u671fNSCLC\u60a3\u8005\u7684\u751f\u5b58\u671f\u65b9\u9762\u4f5c\u7528\u5341\u5206\u6709\u9650\uff0c\u56e0\u6b64\u5bfb\u6c42\u65b0\u7684\u6cbb\u7597\u65b9\u5f0f\u8feb\u5728\u7709\u776b\u3002\u968f\u7740\u5bf9\u80ba\u764c\u53d1\u75c5\u673a\u5236\u53ca\u5176\u751f\u7269\u5b66\u884c\u4e3a\u7684\u6df1\u5165\u7814\u7a76 \uff0c\u5206\u5b50\u9776\u5411\u6cbb\u7597\u5df2\u6210\u4e3a\u6cbb\u7597\u665a\u671fNSCLC\u6700\u5177\u524d\u666f\u7684\u7814\u7a76\u9886\u57df\u3002\u5176\u4e2d\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53-\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs\uff09\u5728\u665a\u671fNSCLC\u6cbb\u7597\u65b9\u9762\u53d6\u5f97\u4e86\u7a81\u7834\u6027\u8fdb\u5c55\uff0c\u5176\u4ee3\u8868\u836f\u7269\u4e3a\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\uff0c\u8fd9\u4e24\u79cdEGFR-TKIs\u5df2\u5728\u5168\u4e16\u754c\u8303\u56f4\u5185\u5f97\u5230\u8ba4\u53ef\u5e76\u88ab\u5e7f\u6cdb\u7528\u4e8e\u665a\u671fNS CLC\u7684\u6cbb\u7597\uff0c\u5c24\u5176\u662f\u5bf9\u4e8eEGFR\u654f\u611f\u7a81\u53d8\u8005\u3002\u7136\u800c\uff0c\u7ecf\u8fc7\u4e00\u6bb5\u65f6\u95f4\uff08\u4e2d\u4f4d\u65f6\u95f4\u4e3a6\u4e2a\u6708-12\u4e2a\u6708\uff09\u7684\u6cbb\u7597\u540e\uff0c\u5927\u90e8\u5206\u60a3\u8005\u4f1a\u5bf9EGFR-TKIs\u4ea7\u751f\u8010\u836f\uff0c\u5176\u8010\u836f\u673a\u5236\u4e3b\u8981\u5305\u62ec \u539f\u53d1\u6027\u548c\u83b7\u5f97\u6027\u8010\u836f\u3002\u7531\u4e8eEGFR-TKIs\u5728\u6539\u5584\u665a\u671fNSCLC\u60a3\u8005\u603b\u751f\u5b58\u671f\u548c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u65b9\u9762\u7684\u7a81\u51fa\u4f5c\u7528\uff0c\u5bf9\u4e8eEGFR-TKIs\u8010\u836f\u673a\u5236\u7684\u63a2\u7d22\u5df2\u6210\u4e3a\u56fd\u5185\u5916\u7814\u7a76\u7684\u70ed\u70b9 \u3002\u8be5\u6587\u7ae0\u5c31EGFR-TKI\u8010\u836f\u673a\u5236\u7684\u7814\u7a76\u8fdb\u5c55\u8fdb\u884c\u4e86\u7efc\u8ff0\u3002 DOI: 10.3779/j.issn.1009-3419.2013.10.07 PMID: 24113007 [PubMed - indexed for MEDLINE]  BACKGROUND AND OBJECTIVE: Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced non-small cell lung cancer (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The exact influence of statins on gefitinib resistance in human non-small cell lung cancer (NSCLC) cells with KRAS mutation alone or KRAS/PIK3CA and KRAS/PTEN comutations remains unclear. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Atorvastatin (1\u2009\u03bcM) plus gefitinib treatment inhibited proliferation, promoted cell apoptosis, and reduced the AKT activity in KRAS mutant NSCLC cells compared with gefitinib alone. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, mutant KRAS-mediated gefitinib insensitivity is mainly derived from failure to disrupt the Kras/Raf and Kras/PI3K complexes in KRAS mutant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Atorvastatin overcomes gefitinib resistance in KRAS mutant NSCLC cells irrespective of PIK3CA and PTEN statuses through inhibition of HMG-CoA reductase-dependent disruption of the Kras/Raf and Kras/PI3K complexes. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND AND OBJECTIVE: It has been known that hepatocyte growth factor (HGF) induces gefitinib resistance in non-small cell lung cancer (NSCLC) cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study is to investigate the involvement of c-Met and its downstream signaling pathway in the HGF-induced gefitinib resistance of NSCLC cells with different epidermal growth factor receptor (EGFR) gene types. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: c-Met and its downstream signaling pathway possibly participated in the HGF-induced gefitinib resistance in NSCLC cells with different EGFR gene types. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study was to evaluate the effects of chemotherapy plus gefitinib versus chemotherapy alone on survival of patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Randomized controlled trials (RCTs) comparing chemotherapy with and without gefitinib in the treatment of patients with advanced NSCLC were included in our analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Some studies showed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) patients with brain metastasis (BM), while the concentration of gefitinib in cerebrospinal fluid (CSF) was low. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: The aim of this study was to explore change and significance of serum carcino-embryonic antigen (CEA) before and after gefitinib therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Forty patients with advanced NSCLCs in III~IV stages were selected as study objects given gefitinib therapy combined with routine local radiotherapy until tumor progression or intolerable toxicity. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Serum CEA level can serve as a biochemical index to evaluate the prognosis with gefitinib treatment for NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy were randomly assigned (1:1) to receive gefitinib 250 mg per day or placebo for 2 years. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Silencing of Notch-1 using siRNA resulted in mesenchymal-epithelial transition (MET), which was associated with impaired invasion and anchorage-independent growth of lung cancer and resensitisation to gefitinib in acquired resistant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for non-small cell lung cancer (NSCLC) brain metastases. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EGFR T790M mutation in the plasma samples obtained from 33 patients with gefitinib-resistant NSCLC was analyzed by the both mutant-enriched PCR and direct sequencing. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR), these poor responders EGFRs lacking activating mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we have attempted to improve TKI response of NSCLC cell lines (A549 and H1299) devoid of EGFR mutations, by combination of gefitinib and 5-ALA/photodynamic therapy (PDT). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Finally, gefitinib anti-tumor efficacy was tested in these patient-derived NSCLC xenograft models. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The range of gefitinib responses in the patient-derived NSCLC xenograft models were consistent with the results reported from clinical trials. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Furthermore, we observed that patient-derived NSCLC models with FGFR1 gene amplification were insensitive to gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We reviewed the medical records of patients with consecutive advanced NSCLC harboring EGFR mutations who underwent gefitinib monotherapy at Okayama University Hospital. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "5.1 months; p = 0.989, log-rank test), suggesting that BSA is a predictive, rather than a prognostic, marker for gefitinib therapy in EGFR-mutated NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, BSA affected PFS in patients with EGFR-mutated NSCLC who underwent gefitinib monotherapy, suggesting the need for appraisal of BSA-based dose adjustment, even for this molecular target-based therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR inhibitors, such as gefitinib, frequently develop drug resistance due to the presence of secondary mutations like the T790M mutation on EGFR exon 20. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A retrospective review was conducted of all patients with stage III/IV NSCLC treated with gefitinib in Peking Union Medical College Hospital from October 2002 to September 2011. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Common treatment modalities for non-small cell lung cancer (NSCLC) involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our purpose was to test ubiquitin-specific peptidase 8 (USP8) as a potential therapeutic target for gefitinib-resistant and -sensitive non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EXPERIMENTAL DESIGN: Testing the effect of knockdown of USP8 and use of a synthetic USP8 inhibitor to selectively kill gefitinib-resistant (or -sensitive) NSCLCs with little effect on normal cells in cell culture and a xenograft mouse model. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Knockdown of ubiquitin-specific peptidase 8 (USP8) selectively kills gefitinib-resistant NSCLCs while having little toxicity toward normal cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We also determined that a synthetic USP8 inhibitor markedly decreased the viability of gefitinib-resistant and -sensitive NSCLC cells by decreasing RTK expression while having no effect on normal cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Moreover, treatment with a USP8 inhibitor led to significant reductions in tumor size in a mouse xenograft model using gefitinib-resistant and -sensitive NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We propose USP8 as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The expression and transcriptional activity of \u03b2-catenin were measured in both the NSCLC cell line PC9 and its sub-line PC9/AB(2) which has acquired resistance to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EXPERIMENTAL DESIGN: The effects of gefitinib, a selective EGFR-TKI, and metformin on a panel of non-small cell lung cancer (NSCLC) cell lines were assessed by using MTT, bromide assay, flow cytometry, anchorage-independent growth, coimmunoprecipitation, and Western blot analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: The combination of metformin with gefitinib induced a strong antiproliferative and proapoptotic effect in NSCLC cell lines that harbored wild-type LKB1 gene. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Metformin and gefitinib are synergistic in LKB1 wild-type NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Polymorphisms of the CYP2D6 gene were analyzed in 55 patients with NSCLC who experienced grade \u2265 2 transaminase elevation from gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we interrogated the hypothesis that the IGF-1R may serve as a biomarker for, and may play a role in, intrinsic resistance to the EGFR-specific TKI gefitinib in NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Total-IGF-1R and phosphorylated (p)-IGF-1R expression levels were related to gefitinib sensitivity in 23 NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The utility of IGF-1R expression as a predictive biomarker was also evaluated by immunohistochemistry (IHC) in 98 primary NSCLC samples from patients treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In primary NSCLC tissues, IGF-1R expression was found to be significantly higher in patients with progressive disease, i.e., showing gefitinib resistance, as compared to those with a complete or partial response. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: IGF-1R acts as a predictor for resistance to gefitinib in NSCLC cell lines and NSCLC patients, but does not seem to play a role in the intrinsic resistance to this drug. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to evaluate the efficacy of radiotherapy in non-small-cell lung cancer (NSCLC) with acquired gefitinib resistance caused by PTEN deficiency to suggest radiotherapy as an alternative to EGFR TKIs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PTEN deficient-mediated gefitinib resistance was generated in HCC827 cells, an EGFR TKI sensitive NSCLC cell line, by PTEN knockdown with a lentiviral vector expressing short hairpin RNA-targeting PTEN. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Chemotherapy with platinum agents is the standard of care for non-small-cell lung cancer (NSCLC); however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We performed this study to investigate the combined inhibitory effect of the mTOR inhibitor RAD001 and the EGFR-TKI gefitinib in three EGFR wild-type NSCLC cell lines: A549 (PIK3CA wild\u2011type), NCI-H460 (PIK3CA mutant) and NCI-H661 (PIK3CA wild-type). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " This retrospective review of a single institution case series study was conducted to correlate the objective response and skin rash of gefitinib in patients with advanced or metastatic non-small-cell lung cancer(NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "One hundred and forty-nine patients with advanced or metastatic NSCLC were treated with gefitinib (250 mg/day) as second line systemic therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus it can be concluded that occurrence of skin rash and female gender were associated with improved survival with gefitinib for recurrent NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung cancer (NSCLC) compared with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: There is no published data in Nepal regarding the use of gefitinib in patients with non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A single institutional retrospective study was conducted for the period from January 2004 to December 2006 involving patients with locally advanced or metastatic NSCLC who received gefitinib as monotherapy Primary objective was to evaluate the objective tumor response rate. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: A total of 36 patients with advanced NSCLC who received gefitinib 250 mg orally once daily as 1st, 2nd, 3rd, and 4th line treatment in 7, 14, 9, and 6 patients respectively were included in the analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we examined the correlation between EGFR gene promoter methylation and the therapeutic effect of gefitinib in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that blockade of DNA methylation may enhance the antitumor effects of EGFR-TKIs and gefitinib in NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Maintenance therapy with gefitinib notably improves survival in patients with advanced non-small cell lung cancer (NSCLC) and EGFR mutation-positive tumors, but the economic impact of this practice is unclear. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The clinical data were primarily obtained from the results of a pivotal phase III trial that assessed gefitinib maintenance treatment in patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: After EGFR genotyping, gefitinib maintenance treatment for advanced NSCLC with EGFR mutations increased the life expectancy by 0.74 years and 0.46 QALYs compared with routine follow-up at an additional cost of $26,149.90 USD ($7,178.20 with the GPAP). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, UPR1282 and UPR1268 are effective against various processes involved in malignancy transformation and progression and may be promising compounds for the future treatment of gefitinib-resistant NSCLCs. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations develop acquired resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This study aims to observe the long-term effects of sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung carcinoma (NSCLC) with failed chemotherapy under the guidance of surface-enhanced laser desorption/ionization (SELDI). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Previous studies have reported that Met might be related to gefitinib resistance in non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The present study aims to explore the mechanism of hepatocyte growth factor (HGF)-induced gefitinib resistance in different gene types of sensitive NSCLC in vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "HGF-induced Met phosphorylation may be an important mechanism of gefitinib resistance in sensitive NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This study was designed to analyze the efficacy of gefitinib as a second-line therapy, according to the clinical characteristics in Korean patients with non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We analyzed chemotherapy-na\u00efve NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Although activating epidermal growth factor receptor (EGFR) mutations are excellent predictors of gefitinib outcome in non-small-cell lung cancer (NSCLC), most patients become resistant to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study was undertaken to evaluate predictors of clinical outcome in patients with NSCLC and with EGFR mutations treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: A total of 170 patients with NSCLC and with EGFR mutations received gefitinib as a first-line (n = 50) and a second-line or more (n = 120) treatment at Seoul National University Hospital. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Tumor burden, expressed as the number of metastatic sites, is predictive of inferior survival in patients with NSCLC and with activating EGFR mutations who are treated with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with advanced/metastatic NSCLC were treated with escalating doses of weekly nimotuzumab (100mg or 200mg, IV) and fixed doses of daily gefitinib (250 mg/day, PO) until disease progression or unacceptable toxicity. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Dual agent molecular targeting of EGFR with nimotuzumab and gefitinib in patients with advanced NSCLC is well-tolerated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Based upon this phase I trial, we are planning to conduct a randomized phase II trial comparing gefitinib and nimotuzumab with gefitinib alone in patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Fifty-one advanced NSCLC patients treated with gefitinib were included in the study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the present study, we investigated the effects of Kv channel blockers in gefitinib-resistant H460 non-small cell lung cancer (NSCLC) cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings suggest that Kv1.1 could serve as a novel therapeutic target for gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) non-small cell lung cancer (NSCLC) after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The current study evaluated the tolerability and efficacy of stereotactic body radiation therapy (SBRT) in combined with gefitinib as a second-line or third-line treatment in patients with advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Treatment of non-small cell lung cancer (NSCLC) with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we synthesized a dozen of novel gefitinib analogues and evaluated their effects on L858R/T790M-EGFR harboring NSCLC cells, and reported that one of these gefitinib mimetics, N-(2-bromo-5-(trifluoromethyl) phenyl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine (hereafter, V1801), triggered apoptosis of the NSCLC cells and overcame gefitinib-resistance in mice inoculated with NCI-H1975 cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Growing clinical evidence supports a personalized approach to non-small cell lung cancer (NSCLC) treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we performed multiple analyses of GPCR expression in a gefitinib-resistant non-small cell lung cancer (NSCLC) cell line, H1975, which harbors an L858R/T790M mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Among them, treatment with either a selective antagonist of adenosine A2a receptors, which were highly expressed in H1975 cell and another gefitinib-resistant NSCLC cells, HCC827GR cells or \"small interfering RNA\" (siRNA) targeting adenosine A2a receptors produced a significant decrease in cell viability of both H1975 and HCC827GR cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The present results suggest that multilayered crosstalk between GPCRs and EGFR may play an important role in orchestrating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Despite excellent clinical response to gefitinib in certain NSCLC patients, nearly all patients who respond initially to gefitinib later develop drug resistance. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this report, we found that benzyl isothiocyanate (BITC) inhibited gefitinib-resistant human NSCLC cells growth by inducing apoptosis in a dose-dependent manner, and activated caspase-3. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Current knowledge of the prognostic biomarkers of advanced non-small cell lung cancer (NSCLC) treated with gefitinib is poor. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSE mRNA as a potential prognostic biomarker of the effectiveness of gefitinib treatment in NSCLC, especially in the Chinese population, needs to be further validated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed 168 advanced NSCLC patients treated with gefitinib between May 2006 and July 2010. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: We found that NSE mRNA expression was inversely correlated with sensitivity to gefitinib in NSCLC patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: For NSCLC patients treated with gefitinib, patients without elevated NSE mRNA had a better prognosis than those with elevated NSE mRNA. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of non-small cell lung cancer (NSCLC), and to date a large amount of clinical data are available. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Here we report 2 cases of non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) gene mutation that developed miliary brain metastases characterized by dementia and disorientation during gefitinib therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that gefitinib concomitant with WBRT is an optional strategy for the treatment of patients with EGFR-mutated NSCLC with miliary metastases to prevent disease flare. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Although epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitors (TKIs) are widely used in the management of advanced non-small cell lung cancer (NSCLC), gefitinib-induced hepatotoxicity has been underappreciated and rarely reported. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Of the 92 NSCLC patients, 6 (6.5%) developed mild to moderate hepatotoxicity during gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: It has been proven that the status of epidermal growth factor receptor (EGFR) gene mutation was related to effects of gefitinib in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study is to reports distribution of EGFR gene mutations in advanced NSCLC and their influence on effect of gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we investigated whether a combination of BMS-754807 and gefitinib would be synergistic in H292 NSCLC and whether [(18)F]fluorothymidine ([(18)F]FLT)-positron emission tomography (PET) could predict the effects. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to explore the potential utility of inhibiting these two pathways with combination of anastrozole and gefitinib in non-small cell lung cancer (NSCLC) cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Terms searched include 'non-small-cell lung cancer', 'NSCLC', 'lung cancer', 'lung tumor', 'gefitinib', 'Iressa', 'EGFR' and 'epidermal growth factor receptor tyrosine kinase inhibitors'. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We used the mammalian target of rapamycin (mTOR) inhibitor everolimus in combination with gefitinib in NSCLC cell lines to analyze the efficacy of this combination regimen and the underlying molecular mechanism. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Acquired gefitinib-resistant cell lines, together with EGFR wild-type and mutant primary gefitinib-resistant NSCLC cell lines, were treated with everolimus alone, gefitinib alone, or the combination of the two drugs, and the effects were evaluated using cell proliferation assays. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The effects of everolimus and gefitinib on the EGFR pathway in NSCLC cell lines were determined by Western blot analysis. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Our data showed that the combination of everolimus and gefitinib exhibits dose-dependent synergism in primary and acquired gefitinib-resistant NSCLC cells. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus, a preclinical rationale exists for the use of everolimus to enhance the efficacy of gefitinib in EGFR-TKI-resistant patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Recent studies have demonstrated that first-line treatment with gefitinib, an epidermal growth factor receptor (EFGR)-targeted tyrosine kinase inhibitor, is significantly superior to standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) harboring EGFR sensitive mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Meanwhile, the efficacy of gefitinib therapy among elderly populations diagnosed with EGFR-mutated NSCLC has not yet been elucidated. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The purpose of this study was to investigate the efficacy and feasibility of gefitinib for chemotherapy-naive patients aged 75 or older with NSCLC harboring EGFR mutations; generally, these patients have no indication for treatment with platinum doublets. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: This is the first study that verified safety and efficacy of first-line treatment with gefitinib in elderly patients having advanced NSCLC with EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Somatic mutations in the epidermal growth factor receptor (EGFR) gene, such as exon 19 deletion mutations, are important factors in determining therapeutic responses to gefitinib in non-small-cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our results indicate that hypoxia causes gefitinib resistance in EGFR-mutant NSCLC through the activation of wild-type EGFR mediated by the upregulation of TGF\u03b1. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The presence of wild-type and mutant EGFR along with tumor hypoxia are important factors that should be considered when treating NSCLC patients with gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We previously demonstrated that the gefitinib-sensitive NSCLC cell line PC9 shows efficient ligand-induced endocytosis of phosphorylated EGFR (pEGFR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In contrast, the gefitinib-resistant NSCLC cell lines QG56 and A549 showed internalized pEGFR accumulation in the aggregated early endosomes, and this was associated with SNX1, a protein that interacts with and enhances the degradation of EGFR upon EGF stimulation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Using immunofluorescence, we demonstrated that transfection of SNX1 siRNA into gefitinib-resistant NSCLC cells resulted in the disappearance of a large amounts of SNX1 staining. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with non-small-cell lung cancer (NSCLC) treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to evaluate the efficacy and safety of gefitinib as a first-line therapy for advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients with advanced NSCLC who did not tolerate or who refused chemotherapy received 250 mg/day of gefitinib orally as first-line therapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "A total of 68 NSCLC patients were enrolled, and the overall response rate (RR) and disease controlled rate (DCR) with gefitinib treatment was 35.3 and 77.9%, respectively. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, first-line therapy with gefitinib is an effective and tolerable treatment regimen for advanced NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In NSCLC cells expressing wild-type EGFR, SHP2 knockdown decreased ERK phosphorylation, basally and in response to gefitinib, and increased cellular sensitivity to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "SAA levels measured by ELISA in 97 NSCLC patients treated with gefitinib correlated with the clinical outcome of the patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND AND OBJECTIVE: The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: A 250 mg dose of gefitinib offers good QoL and is safe for advanced NSCLC long-term survivors even after more than three years of treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of the present study is to determine whether gefitinib, a selective EGFR tyrosine kinase inhibitor, can radiosensitize the NSCLC H358 and HCC827 cell lines. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we investigated the incidence, clinical features, and prognosis of gefitinib-related ILD in Taiwanese patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: A total of 1080 patients with NSCLC, who received at least 1 dose (250 mg per day) of gefitinib treatment, were enrolled. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Taiwanese patients with NSCLC had a relatively high incidence of ILD during gefitinib treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: QoL was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first-line therapy for advanced EGFR-mutated NSCLC in spite of no survival advantage. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "To test whether inhibition of the ER signaling pathway affects the antitumor effect of gefitinib, gefitinib and an ER antagonist, fulvestrant, were administered to NSCLC cell lines with acquired resistance to gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that there is a functional cross-signaling between the EGFR/ER pathways in NSCLC with acquired resistance to gefitinib, possibly providing rationale for combining gefitinib with anti-estrogen therapy for advanced NSCLC treatment. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We treated 13 NSCLC cell lines, including 8 EGFR mutant and 5 EGFR wild type by using gefitinib or small interfering RNAs against EGFR (siEGFR). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To evaluate the efficacies of gefitinib plus radiotherapy in the treatment of brain metastases in non-small-cell lung carcinoma (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The combined regimen of gefitinib plus radiotherapy can improve the therapeutic efficacies of brain metastases and enhance the quality-of-life in NSCLC patients, side effects are tolerable. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: In selected patients with advanced non-small cell lung cancer (NSCLC) the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows response rates of \u2265 70% and a significant prolongation of progression free survival (PFS). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We analyzed pre-therapeutic tissue specimens of a rare and specific subset of previously treated German patients with advanced NSCLC who experienced \u2265 3 year response to gefitinib within the International IRESSA EAP. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The results suggest that FoxM1 plays an important role in the resistance of NSCLC cells to gefitinib in vitro. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PAC1 and epidermal growth factor receptor (EGFR) are present in non-small-cell lung cancer (NSCLC) cells, and the growth of NSCLC cells is inhibited by the PAC1 antagonist PACAP(6-38) and the EGFR tyrosine kinase inhibitor gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Addition of the selective KOR agonist U50,488H to gefitinib-sensitive (HCC827) and gefitinib-resistant (H1975) NSCLC cells produced a concentration-dependent decrease in their growth. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3\u03b2. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Although the presence of epidermal growth factor receptor (EGFR) mutation and good response to gefitinib have been reported in non-small cell lung cancer (NSCLC) patients with miliary brain metastases, the influence of the EGFR mutations on the radiographic features remains unclear. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This was a single-arm, open-label, prospective, phase II trial of gefitinib for the treatment of advanced or metastatic NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to test whether genistein combined with gefitinib is effective against NSCLC in a cell line carrying T790M, and to clarify the underlying mechanisms. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These findings suggest that genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " To define the pathological features associated with response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC, we have evaluated tumor histopathological features and immunohistochemical markers of proliferation (Ki-67) and epithelial mesenchymal transition (EMT) in 36 resected early stage NSCLC from patients treated preoperatively with gefitinib for 28 days. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "drug": "gefitinib", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer (NSCLC) patients with epithelial growth factor receptor (EGFR) mutations and bone metastases are often concurrently administered tyrosine kinase inhibitors (TKIs) and bisphosphonates. ", "drug": "bisphosphonate", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The present work evaluated the in vitro effects of chitosan cross-linked \u03b3-poly(glutamic acid) (\u03b3-PGA) nanoparticles (Nps) loaded with docetaxel (DTXL) and decorated with Cetuximab (CET), targeted to EGFR over-expressing non-small-cell-lung-cancer (NSCLC) cells (A549). ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "On these bases, the combination of docetaxel and nintedanib can be considered a new option for the second-line treatment for patients with advanced NSCLC with adenocarcinoma histology. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In order to improve overall outcomes for patients with advanced NSCLC, both ramucirumab plus docetaxel and the PD-1-blocking antibody should be used in any treatment line. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In several large, randomized studies, PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The current analysis of data indicates that the benefit from PD-1 inhibitors versus docetaxel in second line treatment of NSCLC is limited to the PD-L1>1% subpopulation. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " In non-small cell lung cancer (NSCLC), the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Among these, nivolumab demonstrated a survival benefit versus docetaxel in refractory squamous NSCLC, reporting 41% reduction in risk of death (median overall survival: 9.2 versus 6.0 months; objective response rate: 20% versus 9%), and better safety profile than standard-of-care chemotherapy (grade 3-4 adverse events: 7% versus 55%). ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Areas covered: We searched Medline, Embase, Scopus and Cochrane Library for randomized phase III trials that evaluated docetaxel in various clinical settings of NSCLC and for meta-analyses of such trials and we present all relevant data regarding the pharmacology and clinical use of docetaxel in NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Expert commentary: Despite its diminishing role, docetaxel in combination with novel targeted agents remains an important option of the therapeutic armamentarium in advanced NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "drug": "docetaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This is the first randomized clinical trial that showed a significant and clinical meaningful OS benefit in EGFR mutation-positive NSCLC patients following maintenance therapy with gefitinib as compared to placebo. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus FZKA granules) or control group (gefitinib plus placebo). ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with advanced non-small-cell lung cancer without disease progression after first-line chemotherapy, were published previously. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The results show that monotherapy therapy with EFGR-TKIs produce a significant OS and PFS benefit for patients with NSCLC compared with placebo or BSC, especially for the patients who had adenocarcinomas, non-smokers and patients with EGFR gene mutations. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Maintenance gefitinib significantly prolonged progression-free survival (PFS) compared with placebo in patients from eastern Asian with locally advanced/metastatic non-small-cell lung cancer (NSCLC) after four chemotherapeutic cycles (21 days per cycle) of first-line platinum-based combination chemotherapy without disease progression. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy were randomly assigned (1:1) to receive gefitinib 250 mg per day or placebo for 2 years. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the randomized phase 2b/3 LUX-Lung 1 trial in advanced NSCLC patients who progressed after at least 12 weeks of benefit from EGFR TKIs, afatinib failed to improve overall survival compared to placebo. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This approval was based on an improvement in overall survival (OS) with an acceptable toxicity profile in a randomized, multicenter, double-blinded, placebo-controlled trial of 1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: A computerized search through electronic databases, including PubMed and Embase (until Dec 2014), was performed to obtain eligible randomized controlled trials (RCTs) that compared hypertension and/or QTc prolongation profile of vandetanib alone or plus chemotherapy with control groups (placebo, single targeted therapy, chemotherapy, or a combination of them) in patients with advanced NSCLC. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Eligible studies were randomized clinical trials (RCTs) that compared safety profile of combined therapy inhibiting EFGR and VEGF pathways with control groups (placebo, single EGFR or VEGF inhibition therapy, chemotherapy or a combination of them) in patients with advanced NSCLC. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens. ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "It was evaluated in combination with chemotherapy in two randomised placebo-controlled trials in patients with small cell lung cancer (SCLC, n=724) and advanced non-small cell lung cancer (NSCLC, n=722). ", "drug": "placebo", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). ", "drug": "haemorrhage", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "haemorrhage", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Platinum-based chemotherapy remains as the standard of treatment for most of advanced non-small cell lung cancer (NSCLC) patients, and although therapeutic improvements have been achieved in the last years, the benefits are quite modest. ", "drug": "Platinum-based chemotherapy", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. ", "drug": "Platinum-based chemotherapy", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "Platinum-based chemotherapy", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Several randomized controlled clinical trials have compared therapy with or without thalidomide in the treatment of advanced non-small cell lung cancer (NSCLC). ", "drug": "thalidomide", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We carried out a meta-analysis to determine the efficacy and safety of thalidomide-based therapy in patients with advanced NSCLC. ", "drug": "thalidomide", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "For this meta-analysis, we selected randomized clinical trials that compared thalidomide in combination with other therapy or other therapy alone in patients with advanced NSCLC. ", "drug": "thalidomide", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The addition of thalidomide to other therapy did not improve survival and tumor response in patients with advanced NSCLC, and thalidomide-based therapy was associated with more grade 3/4 dizziness and constipation. ", "drug": "thalidomide", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. ", "drug": "thalidomide", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC. ", "drug": "thalidomide", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in non-small cell lung cancer (NSCLC) cell lines with the rationale of potentially translating these findings into the clinical setting. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "drug": "vinorelbine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "By screening 40 non-small cell lung cancer cell (NSCLC) lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate and sunitinib malate) against human non-small cell lung cancer (NSCLC), breast cancer and colorectal cancer were evaluated in vivo. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "To identify genes that are specifically methylated during the evolution of resistance to anti-EGFR therapeutic agents, we performed a methylation-specific array containing a panel of 56 genes that are commonly known to be regulated through promoter methylation in two parental non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cell lines and their resistant derivatives to either erlotinib or cetuximab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Restoration of DAPK into the resistant NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients' prognosis and quality of life (QoL). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for NSCLC patients with EGFR activating mutation as first-line therapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Targeted therapies directed against epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and afatinib, achieved important improvements in EGFR mutated NSCLC with favorable toxicity profile. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Three EGFR-TKIs, namely afatinib, erlotinib and gefitinib, are currently available for the treatment of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Another trial is now investigating the bene\ufb01cial effects of curcumin plus gefitinib or erlotinib for EGFR-mutant NSCLC, although this trial is ongoing. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The subjects studied were 74 NSCLC patients with common EGFR mutations treated with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant non-small cell lung cancer (NSCLC) patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/non-small cell lung cancer/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in non-small cell lung cancer (NSCLC) patients with drug-sensitive EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even though the therapeutic effect is evident. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated non-small cell lung cancer (NSCLC) resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Non-small-cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Our report highlights the potential benefit of erlotinib for the management of brain metastases refractory over afatinib in patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Applying a focused shRNA screening approach to identify genes whose knockdown can prevent and/or overcome acquired resistance to erlotinib in several EGFR-mutant non-small cell lung cancer (NSCLC) cell lines, we identified casein kinase 1 \u03b1 (CSNK1A1, CK1\u03b1). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " In non-small-cell lung cancer (NSCLC) patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with chemotherapy pretreated NSCLC harbouring EGFR mutations received erlotinib at 50 mg/d until disease progression or unacceptable toxicities. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first- or second-line option for patients with NSCLC with minor EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage non-small cell lung cancer (NSCLC) patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287), a fully human anti-HER3 monoclonal antibody, in combination with erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with previously treated advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: This study enrolled patients with stage IIIB/IV NSCLC with Eastern Cooperative Oncology Group performance status 0-1, life expectancy >3 months and who had progressed after at least one prior course of chemotherapy (excluding erlotinib). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to non-small cell lung cancer (NSCLC) patients has been limited due to emergence of acquired drug resistance. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Eight patients diagnosed with non-small cell lung cancer (NSCLC) (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations within the kinase domain of EGFR. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "P7170 at a well-tolerated daily dose of 20 mg/kg significantly inhibited the growth of NSCLC xenografts independent of different mutations (EGFR, KRAS, or PIK3CA) or sensitivity to erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Our results provide evidence of antitumor activity of P7170 in the erlotinib -sensitive and -insensitive models of NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In contrast, erlotinib is potentially effective for the treatment of EGFR wild-type NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI-sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent non-small cell lung cancer(NSCLC)patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Gefitinib and erlotinib are used to treat advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Although non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "KEY RESULTS: Luteolin exerted significant anti-tumourigenic effects on the EGF receptor L858R/T790M mutation and erlotinib-resistant NSCLC both at the cellular and animal levels. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION AND IMPLICATIONS: Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this study, we evaluated the correlation between EGFR mutations and response to erlotinib in Chinese NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We recruited 36 patients with stage IIIB/IV NSCLC who had failed first-line chemotherapy, and treated them with erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In conclusion, the presence of EGFR mutations could be a marker to predict the therapeutic efficacy of erlotinib and the prognosis in Chinese NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Unexpectedly, we find that EGFR-A763_Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell lung cancer (NSCLC) because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Medical records from 104 patients with NSCLC treated with erlotinib were retrospectively reviewed. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of ge\ufb01tinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for non-small cell lung cancer (NSCLC) brain metastases. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Common treatment modalities for non-small cell lung cancer (NSCLC) involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We describe the patient's disease course and treatment in the context of EGFR TKI therapy and the prognostic factors for long-term clinical outcomes of NSCLC, including the development of erlotinib-induced rash. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Results from recently published, randomized Phase III trials showed that first-line erlotinib significantly prolongs progression-free survival in patients with advanced EGFR mutation-positive NSCLC with favorable tolerability, compared with standard chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations develop acquired resistance. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Treatment of non-small cell lung cancer (NSCLC) with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Growing clinical evidence supports a personalized approach to non-small cell lung cancer (NSCLC) treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of non-small cell lung cancer (NSCLC), and to date a large amount of clinical data are available. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer (NSCLC), especially for those with EGFR-activating mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with non-small-cell lung cancer (NSCLC) treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We analyze efficacy of treatment with erlotinib in patients suffering from advanced stage NSCLC who participated in the multicentre, international phase IV study - MO 18109 TRUST (expanded access clinical program of Tarceva\u2122 in patients with advanced stage IIIB/IV NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage IIIB or stage IV NSCLC who failed one or two previous chemotherapy regimens were treated with flat doses of oral vinflunine from day 1 to day 5 and from day 8 to day 12 every 3\u00a0weeks and erlotinib daily on a continuous basis. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Despite its small sample size, this trial showed that, in patients with EGFR wild-type NSCLC, cabozantinib alone or combined with erlotinib has clinically meaningful, superior efficacy to that of erlotinib alone, with additional toxicity that was generally manageable. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, the benefit of ARBs on OS disappeared in the multivariate analysis.The use of ARBs during erlotinib treatment may prolong OS of patients with metastatic NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "drug": "erlotinib", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum-gemcitabine (PG) in first-line treatment of advanced non-small cell lung cancer (NSCLC) have shown inconsistent findings. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "drug": "gemcitabine", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Considering the disease control rate and the tolerance of patients with advanced NSCLC, pemetrexed is strongly recommended to be used in clinical. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u80bf\u7624\u7ec4\u7ec7\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08epidermal growth factor recetor, EGFR\uff09\u7a81\u53d8\u662f\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08tyrosine kinase inhibitor, TKI\uff09\u6700\u91cd\u8981\u7684\u7597\u6548\u9884\u6d4b\u6307\u6807\uff0c\u4f46\u60a3\u8005\u5e38\u5e38\u56e0\u80bf\u7624\u7ec4\u7ec7\u91cf\u592a\u5c11\u5bfc\u81f4EGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u3002TKI\u53ef\u4ee5\u8bf1\u5bfc\u80bf\u7624\u7ec6\u80de\u51cb\u4ea1\uff0c\u5e76\u4e0e\u8bb8\u591a\u51cb\u4ea1\u76f8\u5173\u57fa\u56e0\u8868\u8fbe\u76f8\u5173\u3002\u901a\u8fc7\u68c0\u6d4bGNAS1\u57fa\u56e0 T393C\u591a\u6001\u6027\uff0c\u63a2\u8ba8\u5176\u4e0eEGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u7684\u590d\u6cbb\u665a\u671fNSCLC\u5c0f\u5206\u5b50TKI\u6cbb\u7597\u7597\u6548\u7684\u5173\u7cfb\u3002 \u65b9\u6cd5 \u5165\u7ec42009\u5e741\u67081\u65e5-2012\u5e744\u670830\u65e5\u5c31\u8bca\u4e8e\u6d59\u6c5f\u7701\u80bf\u7624\u533b\u9662\u7684116\u4f8b\u590d\u6cbb\u665a\u671fNSCLC\u60a3\u8005\uff0c\u6240\u6709\u60a3\u8005\u65e2\u5f80\u5747\u63a5\u53d7\u8fc7\u5316\u7597\uff0c\u8fdb\u5c55\u540e\u63a5\u53d7\u5409\u975e\u66ff\u5c3c\u6216\u5384\u6d1b\u66ff\u5c3c\u9776\u5411\u6cbb\u7597\u3002 \u91c7\u7528\u591a\u805a\u9176\u94fe\u53cd\u5e94\u65b9\u6cd5\u68c0\u6d4b\u60a3\u8005\u5916\u5468\u8840\u767d\u7ec6\u80de\u4e2dGNAS1\u57fa\u56e0T393C\u591a\u6001\u6027\u3002\u91c7\u7528SPSS 18.0\u7edf\u8ba1\u8f6f\u4ef6\u5206\u6790\u3002 \u7ed3\u679c \u603b\u6709\u6548\u738729.3%\uff0cGNAS1\u57fa\u56e0T393C\u5404\u57fa\u56e0\u578b\u60a3\u8005\u95f4\u7684\u6709\u6548\u7387\u65e0\u660e\u663e\u5dee\u5f02\u3002\u76f8\u6bd4GNAS1\u57fa\u56e0\u5176\u5b83\u57fa\u56e0\u578b\uff0cCC\u578b\u75be\u75c5\u63a7\u5236\u7387\u66f4\u4f4e\uff0846.2% vs 73.8%, P=0.039\uff09\u3002\u5355\u56e0\u7d20\u5206\u6790\u4e2d\u4f4dPFS\uff0cCC\u578b\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u65f6\u95f4\u77ed\u4e8e\u5176\u5b83\u57fa\u56e0\u578b\uff082.3\u4e2a\u6708 vs 6.0\u4e2a\u6708\uff0cP=0.005\uff09\uff0c\u800c\u5973\u6027\u957f\u4e8e\u7537\u6027\uff0810.2\u4e2a\u6708 vs 4.6\u4e2a\u6708\uff0cP=0.04)\uff1b\u4e0d\u5438\u70df\u8005\u957f\u4e8e\u6709\u5438\u70df\u53f2\u8005\uff0811.9\u4e2a\u6708 vs 2.5\u4e2a\u6708\uff0cP<0.001)\uff1b\u75c5\u7406\u7c7b\u578b\u4e3a\u817a\u764c\u957f\u4e8e\u5176\u4ed6\u7c7b\u578b\uff0811.9\u4e2a\u6708 vs 4.1\u4e2a\u6708\uff0cP<0.001)\uff0c\u5747\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u5f02\u3002\u591a\u56e0\u7d20\u5206\u6790\u7ed3\u679c\u663e\u793a\uff0c\u5305\u62ec\u5438\u70df\u53f2\u3001ECOG\u8bc4\u5206\u548c\u75c5\u7406\u7c7b\u578b\u3001GNAS1\u57fa\u56e0\u591a\u6001\u6027\u4e3aPFS\u7684\u72ec\u7acb\u9884\u540e\u56e0\u7d20\uff08P=0.006 \uff09\u3002\u7ed3\u8bba \u5bf9\u590d\u6cbb\u665a\u671fEGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u7684NSCLC\uff0cGNAS1\u57fa\u56e0T393C\u57fa\u56e0\u578b\u4e3aCC\u8005\u662f\u63d0\u793a\u8fd1\u671f\u7597\u6548\u8f83\u5dee\u7684\u6307\u6807\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.06 PMID: 24758907 [PubMed - indexed for MEDLINE]  Current pemetrexed/platinum chemotherapy does not produce a satisfactory therapeutic response in advanced lung cancer patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The aim of our study was to investigate the efficacy and safety of pemetrexed monotherapy in chemo-na\u00efve Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients with epidermal growth factor receptor (EGFR) wild-type or unknown advanced non-squamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In this cohort of patients with advanced NSCLC, patients received a platinum agent with or without bevacizumab or pemetrexed, a TKI, or a single agent. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  BACKGROUND: CHFR expression has previously been established as a powerful predictor for response to taxane based first-line chemotherapy in non-small cell lung cancer. ", "drug": "pemetrexed", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here we investigated the hypothesis that AURKB expression modulates the efficacy of taxanes in NSCLC cells. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Aurora B activity is an important modulator of taxane response in NSCLC cells. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This may lead to further insights into taxane sensitivity of NSCLC tumours.British Journal of Cancer advance online publication 17 January 2017. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Randomised controlled trial to evaluate synergy between taxane plus platinum chemotherapy and CADI-05, a TLR-2 agonist targeting desmocollin-3 as a first line therapy in advanced Non Small cell lung cancer (NSCLC). ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: KRAS mutated NSCLC patients treated with taxane-based chemotherapy had best ORR. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Docetaxel, a taxane chemotherapy drug widely used in the treatment of many types of solid tumors including non-small cell lung cancer (NSCLC), rarely causes infiltrative pneumonitis. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  BACKGROUND: CHFR expression has previously been established as a powerful predictor for response to taxane based first-line chemotherapy in non-small cell lung cancer. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Our study evaluated and identified SNPs in key candidate genes in platinating agent and taxane pathways associated with outcome and toxicity in advanced NSCLC. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: DISRUPT evaluated whether adding the vascular-disrupting agent ombrabulin to a taxane-platinum doublet in the first-line setting improved progression-free survival (PFS) in patients with metastatic non-small cell lung cancer (NSCLC). ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: This study did not meet its primary endpoint of improving PFS by adding ombrabulin to a taxane-platinum regimen for first-line treatment of metastatic NSCLC. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: A number of studies have examined the relationship between the expression of the class III \u03b2-tubulin (TUBB3) and the treatment responses to the taxane/vinorebine-based chemotherapy in patients with non-small cell lung cancer (NSCLC). ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The inclusion criteria were the taxane/vinorebine-based chemotherapy in patients with NSCLC and the evaluation of the clinical outcomes in relation to the expression of TUBB3. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The expression level of TUBB3 may be a useful biomarker to predict the clinical outcomes of the taxane/vinorebine-based chemotherapy in patients with NSCLC. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These results suggest that the expression of SGOL1-B causes abnormal mitosis and taxane resistance in NSCLC cells. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we investigated the significance of nuclear expression of the mitotic checkpoint gene checkpoint with forkhead and ringfinger domains (CHFR) as predictor of response and overall survival with taxane-based first-line chemotherapy in advanced stage NSCLC. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: CHFR expression is a novel predictive marker of response and overall survival in NSCLC patients treated with taxane-containing chemotherapy. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The activity and toxicity of eribulin were assessed in patients with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: An open-label phase II study included patients with NSCLC previously treated with platinum and taxane-based therapy, with up to two prior cytotoxic regimens, given for metastatic disease or as adjuvant therapy. ", "drug": "taxane", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PD-L1\u00a0testing is likely to be implemented in daily practice for selection of advanced NSCLC that will be treated with pembrolizumab, underscoring the relevance of ongoing harmonization studies of the use of the different antibodies available for PD-L1\u00a0testing. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The Keynote 024 is randomized, open-label, international, phase III study to evaluate the efficacy of pembrolizumab, an antibody directed to programmed death 1 (PD-1),an immune checkpoint inhibitor, compared with platinum-based chemotherapy in patients with previously untreated advanced NSCLC and PD-L1 expression in at least 50% of the tumour cells. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study establishes the extent of concordance between three validated, commercially available PD-L1 immunohistochemistry diagnostic assays for NSCLC patients (Ventana SP263 [durvalumab], Dako 22C3 [pembrolizumab], and Dako 28-8 [nivolumab]). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The authors discuss pembrolizumab and pembrolizumab plus ipilimumab, durvalumab and durvalumab plus tremelimumab, nivolumab and nivolumab plus ipilimumab for NSCLC as well as nivolumab and nivolumab plus ipilimumab for SCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENT AND METHODS: Patients with advanced non-small cell lung cancer (NSCLC) treated with pembrolizumab at Memorial Sloan Kettering Cancer Center (N=51) as part of KEYNOTE-001 (NCT01295827) were included. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Thyroid dysfunction during pembrolizumab treatment for NSCLC is common and is characterized by early-onset, frequently preceded by transient hyperthyroidism, closely associated with antithyroid antibodies, and may be associated with improved outcomes. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of programed death receptor-1 inhibitors, such as nivolumab and pembrolizumab. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "OBJECTIVE: To assess the efficacy and safety of different dose schedules of pembrolizumab in the treatment of patients with advanced NSCLC and melanoma. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "SELECTION CRITERIA: Prospective clinical trials reporting the outcomes of more than one dose schedule of pembrolizumab in the treatment of advanced NSCLC and melanoma. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression \u226550\u00a0%. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced non-squamous NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This study is a retrospective analysis of patients treated with nivolumab or pembrolizumab for melanoma, non-small cell lung cancer (NSCLC) and renal cancer at Ant\u00f4nio Erm\u00edrio de Moraes Oncology Center, Brazil. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Conclusions In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here, we briefly discuss the PD-1/PD-L1 pathway and pembrolizumab before delving into the clinical trials that have led to its just-mentioned approval in NSCLC and ongoing clinical trials. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Finally, we discuss the use of biomarkers, primarily PD-L1, in the context of pembrolizumab and NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The best characterized checkpoint inhibitors in advanced NSCLC setting are ipilimumab and tremelimumab, (anti-CTLA-4 antibodies), nivolumab and pembrolizumab (anti-PD-1 antibodies), atezolizumab and durvalumab (anti-PD-L1 antibodies). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Nivolumab and pembrolizumab have received the FDA and EMA approval for the treatment of NSCLC in second-line setting. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "More recently the approval of the anti-programmed cell death 1 (anti-PD-1) monoclonal antibodies nivolumab and pembrolizumab for previously treated advanced squamous and non-squamous NSCLC, as well as other immune checkpoint inhibitors delivering promising results, has radically transformed the therapeutic landscape of NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Nivolumab and pembrolizumab (anti-PD1 agents) were recently approved as second-line treatment in NSCLC after progression on platinum-doublets. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Based on these encouraging results, multiple different PD-1/PD-L1 inhibitors have entered clinical development, and two agents (nivolumab and pembrolizumab) have gained regulatory approval in the United States for the treatment of NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this review, we discuss the recent clinical trial results of pembrolizumab, nivolumab, and atezolizumab for NSCLC, and the significance of companion diagnostic testing for tumor PD-L1 expression. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review summarizes clinical trials of nivolumab, pembrolizumab, and atezolizumab in patients with NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In refractory non-small cell lung cancer (NSCLC), pembrolizumab induced ORRs of 19-25%. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Based on these results, pembrolizumab was approved by the USA FDA for the treatment of advanced melanoma and NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this review, we discussed the recent results obtained by immunotherapy in cancer patients and we evaluated the economic impact of recently approved nivolumab and pembrolizumab in patients with advanced melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We aimed to establish the activity and safety of the PD-1 inhibitor pembrolizumab in patients with untreated brain metastases from melanoma or non-small-cell lung cancer (NSCLC). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "More recently, pembrolizumab has also been approved as salvage therapy in PD-L1-positive recurrent NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This article will provide an update on different treatment options available for patients with EGFR wild-type advanced NSCLC who relapse after first-line therapy, which includes essentially ramucirumab, vandetanib, nivolumab, and pembrolizumab and considerations that may allow clinicians to a better choice of agent for second-line therapy. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "At this time, PD-L1 immunohistochemistry (IHC) staining using 22C3 antibody is the only FDA-approved companion diagnostic for patients with NSCLC-treated pembrolizumab, but more are expected to come to market. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The anti-PD-1 antibodies nivolumab and pembrolizumab are approved by the US FDA for treatment of patients with NSCLC and other tumor types. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cell lung cancer (NSCLC). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In 2015, the US Food and Drug Administration (FDA) approved two immuno-oncology agents, the PD-1 inhibitors nivolumab and pembrolizumab, for the treatment of previously treated advanced non-small cell lung cancer (NSCLC). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-designated drug, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 (PD-L1), as determined by an FDA-approved test, and who have disease progression on or after platinum-containing chemotherapy or targeted therapy against anaplastic lymphoma kinase or epidermal growth factor receptor, if appropriate. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Under these regulations, a confirmatory trial or trials is required to verify and describe the benefit of pembrolizumab for patients with metastatic NSCLC.IMPLICATIONS FOR PRACTICE: This report presents key information on the U.S. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Through whole exome sequencing of tumors, investigators have recently described mutational burden in non-small cell lung cancer (NSCLC) was associated with response to pembrolizumab. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In these patients, the recent efficacy demonstration of antibodies against immune checkpoints: the anti-programmed death-1 (PD-1) and anti-programmed death ligand-1 (PD-L1), has led to approval of nivolumab and pembrolizumab (anti-PD-1) in the treatment of advanced NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Ipilimumab, pembrolizumab, and nivolumab are approved by the Food and Drug Administration (FDA) for the treatment of advanced melanoma; nivolumab was also recently approved for metastatic squamous NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Several published studies demonstrate that single-agent pembrolizumab is safe and has efficacy in patients with NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We review the available data on pembrolizumab in NSCLC and examine the role of potential predictive biomarkers of response to therapy. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Immunotherapies directed at the programmed cell death-1 receptor (PD-1) or its ligand (PD-L1) (nivolumab and pembrolizumab) have demonstrated efficacy in both nonsquamous and squamous cell NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition to nivolumab, pembrolizumab is a PD-1 inhibitor under investigation in NSCLC, and atezolizumab (MPDL3280A), durvalumab (MEDI4736), and avelumab (MSB0010718C) are PD-L1 inhibitors under investigation. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Currently, two anti-PD-1 (nivolumab and pembrolizumab) and one anti- PD-L1 (MPDL-3280A) agents are in advanced stages of development in advanced or metastatic non-small cell lung cancer (NSCLC). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "There remain a number of pivotal trials in progress to further evaluate the optimal use of pembrolizumab alone and in combination for melanoma, NSCLC, and other tumor types. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Overall response rate (ORR) was extracted from phase I-III trials investigating nivolumab, pembrolizumab and MPDL3280A for advanced melanoma, non-small cell lung cancer (NSCLC) and genitourinary cancer, and cumulated by adopting a fixed and random-effect model with 95% confidence interval (CI). ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The predictive value of PD-L1 on tumor cells seems to be more robust for anti-PD-1 antibody (nivolumab and pembrolizumab), and in the context of advanced melanoma and NSCLC. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Recently, many trials addressed the role of such therapies for metastatic non-small cell lung cancer (NSCLC) treatment: ipilimumab, tremelimumab, nivolumab and pembrolizumab are immunotherapeutic agents of high relevance in this field. ", "drug": "pembrolizumab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " There is no cure for non-small-cell lung cancer (NSCLC) or pulmonary arterial hypertension (PAH). ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: A meta-analysis of published data was conducted to investigate the overall risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer (NSCLC) who were receiving vandetanib. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A computerized search through electronic databases, including PubMed and Embase (until Dec 2014), was performed to obtain eligible randomized controlled trials (RCTs) that compared hypertension and/or QTc prolongation profile of vandetanib alone or plus chemotherapy with control groups (placebo, single targeted therapy, chemotherapy, or a combination of them) in patients with advanced NSCLC. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "A significant increase in risk was observed for all-grade hypertension (RR 5.58; 95% CI 4.16 to 7.48; P\u2009<\u20090.00001) and grade \u22653 hypertension (RR 4.79; 95% CI 2.31 to 9.93; P\u2009<\u20090.0001) in advanced NSCLC patients who were receiving vandetanib compared with the controls. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Current evidence showed that significant risks in developing hypertension and QTc prolongation exist in advanced NSCLC patients who were receiving vandetanib. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subgroup analysis demonstrated that the pooled incidences of all-grade and high-grade hypertension were 21.8% [95% CI, 15-30.5%] and 7.6% (95% CI, 2.8-18.8%), respectively, among non-small-cell lung cancer (NSCLC) patients, and 32.1% (95% CI: 27.3-37.3%) and 8.8% (5.9%-12.9%), respectively, among MTC patients, and 15.4 (95% CI: 3.2-33.7%) and 3.4% (95% CI: 1%-11.1%) respectively, among non-MTC/NSCLC tumors patients. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "drug": "hypertension", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotoxic chemotherapy (carboplatin and paclitaxel) and gefitinib administration has not been determined. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Patients receiving first-line nab-paclitaxel qw, paclitaxel qw, or paclitaxel q3w for stage IV non-small-cell lung cancer (NSCLC) were identified. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " The role of single-agent nab-paclitaxel in relapsed or platinum-refractory advanced non-small cell lung cancer (NSCLC) has not been well reported in Western populations. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We analyzed the records of stage IV NSCLC patients with relapsed or platinum-refractory disease treated with single-agent nab-paclitaxel at Weill Cornell Medical College between October 2008 and December 2013. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Thirty-one stage IV NSCLC patients received a median of 4 cycles (range 1-40) of nab-paclitaxel. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Single-agent nab-paclitaxel was well tolerated and demonstrated efficacy in advanced NSCLC patients with relapsed or platinum-refractory disease. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Expression of \u03b2V-tubulin was associated with treatment response and PFS following paclitaxel-based chemotherapy of locally advanced and oligometastatic NSCLC patients. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "drug": "paclitaxel", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and melanoma. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that provides a survival benefit to patients with non-small cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "drug": "Bevacizumab", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " Adjuvant cisplatin-based chemotherapy significantly improves outcomes of completely resected early-stage non-small-cell lung cancer (NSCLC) patients. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "EXPERIMENTAL DESIGN: NSCLC patient-derived xenograft models (n=45) were implanted subcutaneously into panels of nude mice and randomization cohorts were treated with either cetuximab, cisplatin, cisplatin plus cetuximab, vehicle control, or else were left untreated. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Using in vitro drug-resistant NSCLC cell models, we provide evidence that acquired cisplatin resistance may reduce the sensitivity of cancer cells to subsequent treatment with a molecular-targeted agent. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "cisplatin", "polarity": 1}, {"disease": "NSCLC", "orig_sen": "The therapeutic efficacy of cetuximab for NSCLC is limited to use as a monotherapy or in combination with chemotherapy. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The objective of the present study was to develop a novel strategy to enhance the therapeutic efficacy of cetuximab for NSCLC by a co-administration with the tumor-penetrating internalizing RGD peptide (iRGD). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Human NSCLC subcutaneous xenograft models established with the A549 cell line in nude mice were treated with 30 mg/kg cetuximab, 4 mg/kg iRGD, cetuximab plus iRGD or phosphate-buffered saline. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In conclusion, iRGD enhances the effects of co-administered cetuximab in an NSCLC model. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The combined application of cetuximab and iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of cetuximab for the treatment of NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Emerging evidence showed improved efficacy with the addition of cetuximab to chemotherapy in advanced non-small cell lung cancer (NSCLC), but the data in oriental population are limited. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The aim of this study is to investigate the efficacy of cetuximab in combination with chemotherapy in Chinese patients with advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC patients receiving cetuximab in combination with chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College were enrolled and retrospectively analyzed. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we aimed to investigate the therapeutic effect of GC7 combined with cetuximab in NSCLC therapy. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: The current study used cell viability assays, EdU incorporation assays, and western blot to detect that the GC7 exhibited synergistic cytotoxicity with cetuximab in NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "RESULTS: CCK-8 assays showed that combined treatment with GC7 and cetuximab significantly inhibited the viabilities in three NSCLC cell lines. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In addition, EdU incorporation assays also indicated that GC7 co-treatment remarkably enhanced the cetuximab sensitivity in NSCLC cells. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: These findings demonstrate that combined treatment with GC7 could enhance cetuximab sensitivity by inhibiting EIF5A2 in NSCLC cells, implying the potential clinical application of GC7 in cetuximab-based chemotherapy for NSCLC patients. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: A panel of NSCLC cell lines (A549, H460, H322, H358, H1299, HCC827, PC9, H1975, and PC9-GR) was used to evaluate in vitro antitumor activity of ER2 and cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Radiation Therapy Oncology Group (RTOG) 0617 was a randomized trial that investigated both the impact of radiation dose-escalation and the addition of cetuximab on the treatment of non-small cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Further investigation using cetuximab in NSCLC with T790M mutation is warranted. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "MATERIALS AND METHODS: A 2-armed phase II, multi-center study (NTR2230) was performed with the aim to assess the effect of cetuximab to concurrent chemoradiotherapy in LA-NSCLC patients (stage II/IIIA/B). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "It was observed that NSCLC cells exhibited enormous differences in responses to cetuximab; cell lines were more intrinsically resistant to cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In resistant cell lines (H1975 and H1650), the efficacy of cetuximab was increased when combined with CYT387, whereas CYT387 alone in low doses exhibited little effect on NSCLC cell proliferation. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In summary, our findings indicated that CYT387 has a potent indirect antitumor activity, and it is also synergistic in its activity in combination with cetuximab against NSCLC tumors, especially with cetuximab intrinsic-resistance tumors. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " To determine if cetuximab combined with chemotherapy is beneficial for patients with advanced NSCLC after failure of first-line chemotherapy and EGFR-tyrosine kinase inhibitors (TKI). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "As a salvage therapy, cetuximab combined with chemotherapy is indeed beneficial for patients with advanced NSCLC after first-line chemotherapy and subsequent EGFR-TKI treatment failure. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In particular, phase III trials have shown a clinically significant survival benefit for addition of the anti-EGFR mAbs cetuximab or necitumumab to a platinum doublet in chemotherapy-na\u00efve patients with advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The combined use of afatinib plus cetuximab emerges as a new possibility for the treatment of patients with advanced NSCLC harboring mutated EGFR after progression on first-generation EGFR TKIs with consequently acquired resistance to TKIs. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Our results indicate that KRAS mutations are associated with inferior survival benefits for NSCLC but not for those treated with chemotherapies integrating cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: In recent years, the combination of cetuximab and chemoradiotherapy (CRT) has been used to treat stage III non-small cell lung cancer (NSCLC); however, limited data are available for Chinese patients. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Herein, we report preliminary data from a phase I/II study testing the combination of cetuximab with inductive chemotherapy, followed by concurrent CRT (CCRT) in Chinese patients with stage III NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Here we review Phase II and III studies examining the role of EGF receptor inhibitors, including tyrosine kinase inhibitors and the monoclonal antibody cetuximab, as adjuvant therapy in resected patients or as part of multimodality treatment for stage III NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "A twenty patient trial (NSCLC cohort) (cetuximab-based regimen) included two participants with EGFR TKI-resistant mutations ((i) exon 20 D770>GY; and (ii) exon 19 LREA plus exon 20 T790M mutations). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVE: The aim of this study was to investigate the effects of combination of icotinib and cetuximab on the acquired drug resistance caused by T790M mutation of EGFR in NSCLC, and provide experimental evidence for rational treatment of NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The combination of icotinib with cetuximab can exert synergistic inhibitory effect on the acquired drug resistance caused by T790M mutation of EGFR in NSCLC H1975 cells, interrupts the EGFR-downstream signaling pathway, and enhances the anticancer activity of chemotherapeutic drugs. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Our results provide further experimental evidence for the clinical studies of combination of icotinib with cetuximab in the treatment of NSCLC patients associated with secondary drug resistance caused by T790M mutation of EGFR. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to systematically evaluate the efficacy and safety of gefitinib and cetuximab-based therapies in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The studies to be used for the comparisons were selected from the available literature on gefitinib and cetuximab-based therapies compared to conventional chemotherapy in patients with advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "As regards efficacy, the risk ratio (RR) of objective response rate and 1-year survival rate between gefitinib and cetuximab-based therapies in patients with advanced NSCLC were 0.99 [95% confidence interval (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, and the mean difference of progression-free survival and overall survival (OS) were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; P=0.0331), respectively. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results demonstrated that cetuximab-based therapy was superior to gefitinib therapy in terms of OS and inferior to gefitinib therapy in terms of AEs, whereas there were no significant differences in terms of efficacy and safety between the two therapies on other endpoints adopted for advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "OBJECTIVES: To evaluate the efficacy and toxicity of chemotherapy plus cetuximab, compared with chemotherapy alone, for advanced non-small cell lung cancer (NSCLC) previously untreated with chemotherapy or epidermal growth factor receptor (EGFR)-targeted drugs. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "SELECTION CRITERIA: Eligible studies were RCTs that compared chemotherapy plus cetuximab with the same chemotherapy alone, in advanced NSCLC, previously untreated with chemotherapy or EGFR-targeted drugs, and measured at least one of the following: overall survival, progression-free survival, one-year survival rate, objective response rate, quality of life, or serious adverse events. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "AUTHORS' CONCLUSIONS: The combination of chemotherapy plus cetuximab is better than chemotherapy alone as the first-line treatment of advanced NSCLC in improving overall survival, while inducing higher rates of some reportedly manageable adverse events. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "To examine mechanisms of acquired resistance, we developed a series of cetuximab-resistant (Ctx(R)) clones derived from the cetuximab sensitive (CtxS) non-small cell lung cancer (NSCLC) cell line H226. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subgroup analyses revealed a significantly increased risk of FN in the following subgroups: cetuximab, NSCLC and treatment duration longer than the median of all trials (3.1months). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The First-Line Erbitux in Lung Cancer (FLEX) trial showed that the addition of cetuximab to chemotherapy followed by weekly cetuximab maintenance significantly improved survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The phase IIIb NSCLC Erbitux Trial (NEXT) trial (NCT00820755) investigated the efficacy and safety of weekly and every 2 weeks cetuximab maintenance therapy in this setting. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Therefore, in patients with advanced NSCLC who were progression-free after four to six cycles of first-line chemotherapy plus cetuximab, weekly and every 2 weeks cetuximab maintenance therapy were associated with similar survival outcomes. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL was overexpressed, activated, and tightly associated with EGFR expression in cells resistant to cetuximab (Ctx(R) cells). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " PURPOSE: To explore in a panel of patient-derived xenograft models of human non-small cell lung cancer (NSCLC) whether high EGFR expression, was associated with cetuximab activity. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "EXPERIMENTAL DESIGN: NSCLC patient-derived xenograft models (n=45) were implanted subcutaneously into panels of nude mice and randomization cohorts were treated with either cetuximab, cisplatin, cisplatin plus cetuximab, vehicle control, or else were left untreated. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "By screening 40 non-small cell lung cancer cell (NSCLC) lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Absence of rash after 21 days of cetuximab therapy and the serum proteomic classifier, but not ordinal rash severity, were associated with NSCLC outcomes. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: Four randomized phase II/III trials investigated the addition of cetuximab to platinum-based, first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The addition of cetuximab to platinum-based, first-line chemotherapy for advanced NSCLC significantly improved outcome for all efficacy endpoints with an acceptable safety profile, indicating a favorable benefit/risk ratio. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Antibodies targeting epidermal growth factor receptor (EGFR), such as cetuximab, may potentially improve outcome in non-small cell lung cancer (NSCLC) patients with high EGFR expression. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: Available preclinical and phase 2 clinical data suggest that the addition of cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), to chemotherapy might improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We aimed to assess whether the addition of cetuximab to chemotherapy improved progression-free survival in patients with recurrent or progressive NSCLC after platinum-based therapy. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "A pilot study for poor-risk stage III NSCLC patients was conducted combining cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor receptor (EGFR), with chest radiation (RT). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Concurrent weekly cetuximab/chest RT followed by maintenance cetuximab for poor-risk stage III NSCLC was well tolerated. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "We evaluated the integration of cetuximab in the combined modality treatment of stage III non-small cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: The addition of cetuximab to chest radiotherapy and consolidation chemotherapy was tolerated well and had modest efficacy in stage III NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "cetuximab), in combination with chemotherapy, have demonstrated improved outcomes, particularly for subsets of NSCLC patients, but further validations are needed. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In advanced non-small-cell lung cancer (NSCLC), high EGFR expression was identified as a tumour biomarker that can predict survival benefit associated with the addition of cetuximab to first-line chemotherapy. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "INTERPRETATION: The addition of cetuximab to chemotherapy improved survival in the first-line treatment of recurrent/metastatic SCCHN and KRAS wild-type mCRC regardless of tumour EGFR expression level, indicating that in contrast to findings in NSCLC, EGFR expression level is not a clinically useful predictive biomarker in these settings. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "This review focuses on the chimeric monoclonal antibody, cetuximab, its application in the treatment of NSCLC, and the biomarkers that may guide its use in the clinical setting. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The role of cetuximab in the treatment of advanced non-small cell lung cancer (NSCLC) is currently unclear. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The molecular target of cetuximab, epidermal growth factor receptor (EGFR), as measured by FISH, has shown potential as a predictive biomarker for cetuximab efficacy in NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved overall survival in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "To identify genes that are specifically methylated during the evolution of resistance to anti-EGFR therapeutic agents, we performed a methylation-specific array containing a panel of 56 genes that are commonly known to be regulated through promoter methylation in two parental non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cell lines and their resistant derivatives to either erlotinib or cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Restoration of DAPK into the resistant NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the current study we have examined, in different NSCLC cell lines, the combined effect of RNA interference targeting the EGFR mRNA, and inactivation of EGFR signaling using different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Thus platinum-based chemotherapy combined with cetuximab represents a new treatment option for patients with advanced NSCLC and high EGFR expression in their tumors. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Based on sound preclinical evidence and recent data from patients with stage III NSCLC and head and neck cancer, we hypothesize that cetuximab might be an investigational agent that merits further evaluation. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In particular, phase III trials have shown a clinically significant survival benefit for addition of the anti-EGFR mAbs cetuximab or necitumumab to a platinum doublet in chemotherapy-na\u00efve patients with advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The combined use of afatinib plus cetuximab emerges as a new possibility for the treatment of patients with advanced NSCLC harboring mutated EGFR after progression on first-generation EGFR TKIs with consequently acquired resistance to TKIs. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " The aim of this study was to systematically evaluate the efficacy and safety of gefitinib and cetuximab-based therapies in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The studies to be used for the comparisons were selected from the available literature on gefitinib and cetuximab-based therapies compared to conventional chemotherapy in patients with advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "As regards efficacy, the risk ratio (RR) of objective response rate and 1-year survival rate between gefitinib and cetuximab-based therapies in patients with advanced NSCLC were 0.99 [95% confidence interval (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, and the mean difference of progression-free survival and overall survival (OS) were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; P=0.0331), respectively. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "The results demonstrated that cetuximab-based therapy was superior to gefitinib therapy in terms of OS and inferior to gefitinib therapy in terms of AEs, whereas there were no significant differences in terms of efficacy and safety between the two therapies on other endpoints adopted for advanced NSCLC. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In the current study we have examined, in different NSCLC cell lines, the combined effect of RNA interference targeting the EGFR mRNA, and inactivation of EGFR signaling using different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": " BACKGROUND: This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "cetuximab", "polarity": 0}, {"disease": "NSCLC", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "cetuximab", "polarity": 0}]